# 1 Variability in proteoglycan biosynthetic genes reveals new facets of

# 2 heparan sulfates diversity. A systematic review and analysis

- Mohand Ouidir Ouidja, Denis S.F. Biard<sup>a,b</sup>, Sandrine Chantepie<sup>a</sup>, Xavier Laffray<sup>a</sup>, Gael Le Douaron<sup>a</sup>, Minh-Bao Huynh<sup>a</sup>, Nicolas Rebergue<sup>a</sup>, Auriane Maïza<sup>a</sup>, Karla Rubio<sup>a,c,1</sup>, Oscar
- 5 González-Velasco<sup>d</sup>, Guillermo Barreto<sup>a,c,1</sup>, Javier De Las Rivas<sup>d</sup>, and Dulce Papy-Garcia<sup>a,\*</sup>

6 <sup>a</sup> Univ Paris Est Creteil, Glycobiology, Cell Growth and Tissue Repair Research Unit (Gly-CRRET),

7 Creteil, France. <sup>b</sup> - CEA, Institut de Biologie François Jacob (IBFJ), SEPIA, Université Paris-Saclay,

8 Fontenay-aux-Roses, France. <sup>c</sup> Lung Cancer Epigenetic, Max-Planck-Institute for Heart and Lung

9 Research, Bad Nauheim, Germany. <sup>d</sup> Bioinformatics and Functional Genomics Group, Cancer 10 Research Center (CiC-IMBCC, CSIC/USAL/IBSAL), University of Salamanca (USAL), Salamanca,

11 Spain.

<sup>12</sup> <sup>1</sup> Present address: Université de Lorraine, CNRS, Laboratoire IMoPA, UMR 7365, F-54000 Nancy, France.

\* Correspondence to Dulce Papy-Garcia: Gly-CRRET, University Paris Est Creteil, 61 Av General
 de Gaulle, 94010 Créteil, France. <a href="mailto:papy@u-pec.fr">papy@u-pec.fr</a>

15 Keywords: Systematic review and analysis, heparan sulfate proteoglycans, core protein, linker 16 tetrasaccharide, heparan sulfate, biosynthetic genes, clinical variants, expression, sulfotransferases, 17 stimuli.

## 18 Abstract

19 Proteoglycans are complex macromolecules formed of glycosaminoglycan chains covalently linked 20 to core proteins through a linker tetrasaccharide common to heparan sulfate proteoglycans (HSPG) and chondroitin sulfate proteoglycans (CSPG). Biosynthesis of a single proteoglycan requires the 21 expression of dozens of genes, which together create the large structural and functional diversity 22 23 reflected by the numerous diseases or syndromes associated to their genetic variability. Among 24 proteoglycans, HSPG are the most structurally and functionally complex. To decrease this 25 complexity, we retrieved and linked information on pathogenic variants, polymorphism, expression, and literature databases for 50 genes involved in the biosynthesis of HSPG core proteins, heparan 26 27 sulfate (HS) chains, and their linker tetrasaccharide. This resulted in a new gene organization and 28 biosynthetic pathway representation in which the phenotypic continuum of disorders as 29 linkeropathies and other pathologies could be predictable. Moreover, ubiquitous NDST1, GLCE, 30 HS2ST1, and HS6ST1 appeared to generate ubiquitous heparan sulfate (HS) sequences essential 31 for normal development and homeostasis, whereas the tissue restricted NDST2-4, HS6ST2-3, and 32 HS3ST1-6 appeared to generate specialized HS sequences mainly involved in responsiveness to 33 stimuli. Supported by data on genetic polymorphism and clinical variants, we afford a new vision of 34 HSPG involvement in homeostasis, disease, vulnerability to disease, and behavioral disorders.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 35 **1.** Introduction

36 Proteoglycans are a family of macromolecules involved in virtually all aspects of cell biology and 37 physiology<sup>1</sup>. These complex molecules consist in a core protein carrying one or several 38 glycosaminoglycan (GAG) chains, either chondroitin sulfates (CS), heparan sulfates (HS), keratan 39 sulfates (KS), or combinations of them. In HS proteoglycans (HSPG) and CS proteoglycans (CSPG), the glycanic chain is connected to their core proteins trough a common GAG-core protein linker 40 tetrasaccharide (GAG-CP) (Fig. 1)<sup>1-3</sup>. Both the identity of the core protein and the structure of the 41 42 glycanic chain confer to proteoglycans a great functional diversity, as reflected by the multiplicity of diseases or syndromes resulting from defects on genes coding for their biosynthetic machinery. 43 44 Among proteoglycans, HS proteoglycans (HSPG) display the greater structural and functional 45 diversity. This is principally due to the diversity and differential expression of the numerous genes 46 required for their synthesis (Fig. 1). Interestingly, whereas various of these genes are essential for 47 normal development and homeostasis, several others are not, suggesting that some, but not all, 48 HSPG play essential biological roles depending on the core protein and associated HS chains 49 generated in each tissue and cell by its HSPG biosynthetic machinery.

he biosynthesis of HSPG starts in the endoplasmic reticulum with the production of the core protein coded by a single gene (for instance *HSPG2*, *AGR*, *COLXVIIA*, *GPCs*, or *SDCs* that code for full time HSPG core proteins). At the Golgi, the core protein is glycosylated to first form the GAG-CP linker tetrasaccharide. This requires the expression of several genes coding for different enzymes including glycosyltransferases (*XYLT1*, *XYLT2*, *B4GALT7*, *B3GALT6*, *B3GAT3*)<sup>4,5</sup>, kinases (*FAM20B*)<sup>6</sup>, phosphatases (*PXYLP1*)<sup>7</sup>, and nucleosidases (*CANT1*)<sup>8</sup>, as well as nucleoside transporters (*SCL26A2*, *SLC35A2*, and *SLC35A3*)<sup>9</sup> and ion transporters (*SLC10A7*)<sup>10</sup> (Fig. 1).




Fig. 1. Schematic representation of a HSPG and their biosynthetic genes. HSPG are made of a core protein
 (CP) carrying a glycosaminoglycan-CP linker tetrasaccharide (GAG-CP linker) in which either heparan sulfate (HS)
 or chondroitin sulfate (CS) chains are elongated. The HS chain is formed by constitutive disaccharides composed
 of a uronic acid (GIcA or IdoA) and a glucosamine (GIcNAc, or GIcNS) carrying different sulfation and IdoA contents.
 NS domains carry high *N*-sulfation and IdoA levels; NA/NS domains carry intermediary *N*-sulfation, *N*-acetylation,
 and IdoA levels; NA domains are not sulfated and carry not IdoA. The GAG-CP linker biosynthetic genes are
 common to HSPG and CSPG biosynthetic machineries.

64 After formation of the GAG-CP linker, HS chain initiation starts through action of EXTL3 (coded by 65 EXTL3), which adds a N-acetyl glucosamine (GlcNAc) to the non-reducing end of the GAG-CP linker. HS chain elongation continue by sequential addition of GIcA and GIcNAc catalyzed by EXT1/EXT2 66 (coded by EXT1 and EXT2). During chain elongation, epimerization of glucuronic acid (GlcA) into 67 68 iduronic acid (IdoA) is then carried by C5 epimerase (coded by GLCE)<sup>11</sup> and sulfation occurs at 69 different position of the uronic acid and glucosamine residues. Sulfation of IdoA is assured by 2-O-70 sulfotransferase (HS2ST1), whereas sulfation of GlcNAc is assured by N-deacetyl-N-71 sulfotransferases (coded by NDST1, NDST2, NDST3, or NDST4), 6-O-sulfotransferases (coded by 72 HS6ST1, HS6ST2, or HS6ST3), and 3-O-sulfotransferases (coded by HS3ST1, HS3ST2, 73 HS3ST3A1, HS3ST3B1, HS3ST4, HS3ST5, or HS3ST6)<sup>3,12</sup>. During biosynthesis, the HS chain 74 elongation can be stopped by the unproductive glycosyltransferases EXTL1 or EXTL2 (coded by EXTL2 or EXTL1)<sup>13</sup>, whereas after secretion of the HSPG at the extracellular space 6-O-sulfatases 75 76 SULF1 and SULF2 (coded by SULF1 and SULF2) and heparanase (coded by HPSE) can modify the HS chain structures<sup>14-16</sup>. Globally, this process leads to formation of different HS structural 77 78 domains<sup>3,17</sup>. 'NA' domains carry unsulfated *N*-acetylated sequences, 'NA/NS' domains carry HS 79 sequences with intermediary levels of sulfation and IdoA, and 'NS' domains carry high levels of sulfation and IdoA<sup>3,17</sup> (Fig. 1). 80

81 Regardless of their structural diversity, HS are frequently referred as a single ubiquitous molecule, 82 possibly because their structural characterization is highly complex and yet beyond reach. Here, as an approach to reduce HSPG complexity, we propose a new strategy based in a PRISMA<sup>18</sup> 83 84 systematic review and analysis of well stablished pathogenic variants and emerging genetic wide 85 association studies (GWAS) linking HSPG biosynthetic machinery gene variability to disease, 86 susceptibility to disease, altered response to instigating stimuli, or altered behaviors. To confirm the 87 documented clinical variants and traits in human, we compared them to the phenotypes of 88 corresponding gene null mouse, when available. Expression patterns in different organs or tissues 89 were retrieved from gene expression databases and information on structural features, including 90 substrate specificities for enzymes, or protein-protein interactions for core proteins and other biosynthetic proteins, were reviewed following the PRISMA guidelines<sup>18</sup>. Association of this body of 91 92 information resulted in a new HSPG vision that gives a better understanding of the involvement of 93 each biosynthetic gene in the generation of HS sequences carrying structures that can play either 94 ubiquitous or specialized roles in the maintain of tissue homeostasis, disease, behavior disorders, 95 proper tissue response to instigating stimuli, and tissue specific vulnerability to disease.

## 96 2. Methods

Guidelines for Systematic Reviews and Meta-Analyses (PRISMA 2020)<sup>18</sup> were followed to setup a
step-wise method (Fig. 2) for selecting and filtering research items on 50 genes directly involved in
the biosynthesis of HSPG (Table S1). For each HSPG biosynthetic gene, research items were

organized to screen clinical variants, single nucleotide polymorphism (SNP), expression levels in
 different organs of the human body, and literature records databases on substrate selectivities and
 protein-protein interactions.

### 103 **2.1.** Search in clinical variants and SNP databases

104 For each human gene (Table S1), clinical variants and SNP public databases accessible without restriction were consulted by using gene names previously confirmed by MeSH (Medical Subject 105 106 Headings: https://www.ncbi.nlm.nih.gov/mesh/). Data on the impact of gene variability in health status were obtained from three main databases (Fig. 2A): 1) the ClinVar archive (database ClinVar: 107 108 https://www.ncbi.nlm.nih.gov/clinvar/intro/), which gives information on correlations between genetic 109 variations and overt phenotypes or health status with history of interpretations, 2) the Orphanet 110 archive (Database Orphanet: https://www.orpha.net/), which considers clinical presentation based 111 on published scientific articles and expert reviews, and 3) the dbSNP archive (database: 112 https://www.ncbi.nlm.nih.gov/snp/), which is a free public archive for genetic variation within and 113 across different species. For clinical variants, only monogenic variants (indel, deletions, duplications, 114 insertions, and single nucleotide) were considered. Clinical significance was further confirmed in web 115 platforms including Online Mendelian Inheritance in Man (OMIM) (https://www.omim.org/) and the 116 Database of Genomic Variants Archive (DGVa database: <u>https://www.ebi.ac.uk/dgva/</u>). Information 117 on clinical variants overt phenotypes in human were confirmed by literature research on case reports 118 and on reports on the corresponding gene null mice (Methods section 2.3 and Fig. 2C-2D).

#### 119 **2.2.** Search in expression databases

120 Information on the basal expression of the HSPG biosynthetic genes (Table S1) in different tissues 121 or organs of the healthy adult human body was retrieved from open access transcriptomic data bases 122 including: 1) the RNA-seq 32Uhlen project (database 32Uhlen: 123 http://www.proteinatlas.org/humanproteome), which analyzed 32 different tissues from 122 human 124 individuals, 2) the RNA-Seq CAGE (Cap Analysis of Gene Expression) in the RIKEN FANTOM5 125 project (database FANTOM5: http://fantom.gsc.riken.jp/data/), which analyzed several healthy adult 126 human tissues, and 3) the ENCODE strand-specific RNA-seg of 13 human tissues from Michael Snyder's lab (Database ENCODE: https://www.encodeproject.org/). All these RNA-seq databases 127 128 are considered in the expression atlas (http://www.ebi.ac.uk/gxa)<sup>19</sup>, as they use standardized 129 methods that allow the determination of baseline gene expression across controlled biological 130 replicates checked for high quality (good quality raw files and good quality reference genome build 131 are available). The original raw and processed data files can be found in the ArrayExpress platform (https://www.ebi.ac.uk/arrayexpress/), in which the raw single-channel microarray intensities were 132 133 normalized either using an oligo package from Bioconductor (Affymetrix data) or by quantile 134 normalization by the limma package (Agilent data). The data quality was assessed using the 135 arrayQualityMetrics package in R. Quality-trimmed reads were mapped to the latest version of the

reference genome from Ensembl using TopHat2. For each HSPG biosynthetic gene, the number of mapped reads per gene were summed (raw counts) using htseq-count and represented as average transcripts per million (TPM). When transcripts were detected in a tissue, regardless of their level of expression, a gene was considered to be basally expressed in that tissue. To illustrate gene expression, the best TPM value from the different databases was included in the analysis.




Fig. 2. Schematic representation for collecting articles process following PRISMA<sup>18</sup> recommendations. A)
 Clinical variants databases were used to document the effect of HSPG biosynthetic genes variabilities in health status.
 B) Expression databases were used to document organs or tissues in which transcript for each of the genes can be detected under basal homeostasis (healthy status). C) Bibliographic databases were used to document reports on the effect of genetic variability in health status and to expression in organs and tissues. D) Bibliographic databases were also used to document proteins interactions between biosynthetic machinery proteins and substrates selectivities for biosynthetic enzymes.

## 148 **2.3.** Search in literature databases

149 PRISMA guidelines<sup>18</sup> were used to carry two campaigns of literature research for each gene. The 150 first campaign was performed to confirm information obtained from clinical variants databases 151 (section 2.1 and Fig. 2A) by search of clinical variants case reports and reports on the corresponding 152 gene null mouse (Fig. 2C). The second campaign was performed to retrieve information on each 153 gene product functionally, including structural features for substrate specificity and selectivity for 154 enzymes, and on protein-protein interactions for core proteins and other biosynthetic proteins (Fig. 155 2D). Three literature search database thesauruses (PubMed, Scopus, and Science Direct) were 156 employed for a systematic search facilitating an extensive inclusion (Fig. 2C and 2D). For each search engine, 2 subsets of pool keywords and Boolean logic were conducted for each of the 45 157 genes. The first keywords subset (('gene symbol') AND (mutation OR SNP OR polymorphism OR 158

159 deficit OR disease OR "risk factor" OR "knockout mouse" OR "null mouse")) was used to review the effect of genetic variability in health status (Fig. 2C). The second keywords and Boolean logic subset 160 161 was used to review the substrates specificities for enzymes or protein-protein interactions (('protein name' OR 'protein symbol') AND (substrate OR "substrate structure" OR "substrate specificity" OR 162 163 interaction OR "interaction specificity")) (Fig. 2D). References were screened in accordance with title 164 and abstract. Only research articles and literature reviews were considered. Only reports in English 165 language were included. We did not specify a time frame in our literature search. An email alarm 166 system, on each database, was created for notifications on new publications related to the search 167 terms. All reports sorted in the three databases were exported to a common file for each gene in a 168 bibliographic management system (EndNote) and an automatic deduplication tool was applied to 169 discard duplicated reports. Then, reports in species other than human and mouse and reports in 170 cancer cell lines were systematically excluded, unless any example of SNP could be found in human. 171 A pilot user study was then conducted for examining full text reports and representative references 172 were selected and pooled in a single bibliographic management file using EndNote. The reference 173 list of the retrieved reports was also explored, articles non available were requested to authors via 174 email, otherwise references could not be included. Finally, our systematic review included a 175 synthesis of 254 peer-reviewed reports that were checked and review as representative of the full 176 retrieved data (200 reports cited in main text and additional 54 only cited in Suppl. Inf.).

## 177 **3. Results**

## 178 **3.1.** Essential and non-essential HSPG biosynthetic genes

179 A first clustering of the HSPG biosynthetic genes was performed on the bases of their requirement 180 for normal embryonic development and homeostasis, as reported by clinical variants databases. 181 Information on gene essentialness were confirmed by literature records in cases reports and/or from 182 reports on the corresponding gene null mouse (see extended review on genes in Suppl. Inf.). Genes considered essential for normal embryonic development and homeostasis were those for which 183 genetic variability in human is causative of diseases or syndromes, and which corresponding null 184 185 mouse dies or shows overt phenotypes, consistent with that observed in clinical variants. Genes for 186 which genetic variability has not been reported as causative of human diseases or syndromes. 187 and/or for which the corresponding null mouse is viable, fertile, lives normally, and shows non-overt 188 phenotypes in the absence of stimuli, were considered non-essential for normal embryonic 189 development and homeostasis (Suppl. Inf.). However, most of the 'Non-essential' genes show some 190 genetic variability associations with altered responsiveness to stimuli, altered behaviors, or are 191 involved in vulnerability to altered conditions health conditions or behaviors (Suppl. Inf.). Based in 192 these criteria, 2 clusters of genes were formed, the first cluster is referred as 'Essential', and the 193 second as 'Non-essential' (Fig. 3). To avoid loss of clustering, HSPG biosynthetic genes involved in 194 tumor development and growth was not considered, as most HSPG are altered in cancer<sup>16,20,21</sup>.




Fig. 3. First clustering of HSPG genes depending on their requirement for normal development and homeostasis. 'Essential' genes are those for which genetic variability in human is causative of diseases or syndromes and/or the corresponding null mouse dies or shows overt phenotypes consistent with what is observed in clinical variants. \*They can show SNP. 'Non-essential' genes are those for which genetic variability has not been reported as causative of human diseases or syndromes and/or for which the corresponding null mouse is viable, fertile, lives normally, and shows non-overt phenotypes in the absence of stimuli, although many of them show SNP associations with altered responsiveness to stimuli, altered behaviors, or are involved in vulnerability to disease.

#### 202 **3.2.** Ubiquitous and tissue restricted HSPG biosynthetic machinery genes

203 To get additional information on Essential and Non-essential HSPG biosynthetic genes in relation 204 with their basal expression in human, genes were re-clustered depending on their expression in 205 healthy organs or tissues, as documented in RNAseq databases (see Methods). Genes which 206 transcripts were detectable in all analyzed organs were considered as 'widely expressed', whereas 207 genes which expression was only detected in some tissues/organs were considered as 'restrictedly 208 expressed' (Fig. 4 and Supp. Inf.). This transcription-based re-clustering resulted in the HSPG 209 biosynthetic genes organization in four groups of genes (Fig. 4): Group I, Group III, Group III, and 210 Group IV, each of which is described below (simplified clustering is presented in Fig. 5). A review on 211 each gene is detailed in Suppl. Inf.

#### **3.2.1.** Group I - Essential HSPG biosynthetic genes that are ubiquitously expressed

The Group I of HSPG biosynthetic genes clustered widely expressed genes that are essential for 213 214 normal development and homeostasis (Fig. 4, simplified Fig. 5, and Suppl. Inf). This included genes coding for pericellular core proteins HSPG2<sup>22-25</sup>, AGRN<sup>26-29</sup>, and COL18A1)<sup>30-32</sup>, for some 215 membrane-associated core proteins (GPC3<sup>33-35</sup>, GPC4<sup>36,37</sup>, GPC6<sup>38-40</sup>), and for all the genes coding 216 for the GAG-CP linker biosynthetic proteins, including glycosyl transferases (XYLT1<sup>41,42</sup>, XYLT2<sup>43</sup>, 217 B4GALT7<sup>44,45</sup>, B3GALT6<sup>46,47</sup>, and B3GAT3<sup>48</sup>), kinase FAM20B (FAM20B)<sup>49</sup>, phosphatase 218 (PXYLP1)<sup>7</sup>, ion or nucleotide transporters (SLC10A7<sup>10</sup>, SLC26A2<sup>50</sup>, SCL35A2<sup>51</sup>, and SCL35A3<sup>9,52</sup>), 219 220 or other Golgian enzymes (CANT1)<sup>8</sup>. Importantly, Group I also clustered genes coding for the glycosyltransferases that assure HS chain initiation and elongation (*EXTL3*<sup>53,54</sup>, *EXT1*<sup>55</sup>, *EXT2*<sup>56</sup>), for 221 222 epimerase (GLCE)<sup>57</sup>, and for three sulfotransferases (NDST1, HS2ST1, and HS6ST1)<sup>58-61</sup>. 223 Moreover, SULF2, which codes for one of the extracellular 6-O-sulfatase that generates biologically 224 active HS sequences resulting from the cleavage of 6-O-sulfated groups<sup>14,62</sup>, also clustered in Group I. Altogether, the enzymes coded by the ubiquitous HS chain biosynthetic genes can then produce ubiquitous HS sequences (uHS), which fine structures might depend on the expression levels of each biosynthetic gene in each particular cell or tissue<sup>63-65</sup>, as well as in their transcriptional regulation and translational control<sup>66</sup>. Together, this body of data suggests that the Group I HSPG biosynthetic machinery can, by itself, produce HSPG carrying biologically relevant HS sequences or chains that are essential for normal development and homeostasis.

### **3.2.2. Group II - Essential tissue restricted HSPG biosynthetic genes**

232 Group II clustered HSPG biosynthetic genes that, although essential, show tissue restricted 233 expression. Based in current available data and literature records, only HPSE2 clustered in this 234 group (Fig. 4, Fig. 5, and Suppl. Inf). HPSE2 codes for the enzymatically inactive heparanase 2. 235 Although it does not affect HS structures, heparanase 2 can bind to these polysaccharides with 236 higher affinity than the enzymatically active heparanase (Group III), avoiding its enzymatic action 237 and maintaining long HS chains in their biological environment<sup>67,68</sup>. HPSE2 is here reported as the 238 only gene in Group II, but the evolving literature and clinical reports might further enrich the number 239 of genes in this group.

## 240 **3.2.3.** Group III - Non-essential HSPG biosynthetic genes that are ubiquitously expressed

241 Group III clustered HSPG biosynthetic genes that although widely expressed are non-essential for 242 normal development and homeostasis (Fig. 4, Fig. 5, and Suppl. Inf.). However, genes in Group III 243 appeared to be required for appropriate tissue responsiveness to stimuli and, for several of them, SNP is associated with increased or decreased vulnerability to disease, or to altered conditions or 244 behaviors (Supp. Inf). Interestingly, all syndecans core proteins coding genes (SDC1<sup>69-71</sup>, SDC2<sup>72</sup>, 245 SDC3<sup>73-76</sup>, and SDC4<sup>77-79</sup>) and one glypican (GPC1<sup>80,81</sup>) clustered in this group (Fig. 4). Concerning 246 247 the HS chain biosynthetic genes, none of these clustered in this group. Instead, Group III clustered genes involved in the control of HS levels and guality, including EXTL2<sup>82,83</sup>, HPSE<sup>84-86</sup> and 248 249 SULF1<sup>70,87-89</sup> (Fig. 5). Globally, data from GWAS, knockout mice, and literature research indicate 250 that genes in Group III are not essential for normal development and homeostasis but are required 251 for proper response to stimuli and or involved in vulnerability or resistance to disease and altered 252 behaviors.


## 253 **3.2.4.** Group IV - Non-essential HSPG biosynthetic genes that are restrictedly expressed


Group IV of HSPG biosynthetic machinery genes clustered all genes that are expressed in a tissue restricted manner (Fig. 4) and which genetic variability is not causative of lethality or disease, although SNP might be associated to resistance or vulnerability to pathologic conditions, to altered response to stimuli, and to altered behaviors (Fig. 4, Fig. 5, and Suppl. Inf). Genes in Group IV included those coding for two core proteins (*GPC2*<sup>90-92</sup> and *GPC5*<sup>93-95</sup>), three NDSTs (*NDST2*<sup>96-98</sup>,

| (                    | GROUP | ,      | CHROMOSOME                              | anssit<br>gene  | SMOOTH MUSCLE                         | SKIN                                  | ADIPOSE TISSUE                         | URINARY BLADER                         | OVARY                                  | PROSTATE                               | TESTIS                                 | ENDOMETRIUM                            | PLACENTA                               | LUNG                                    | KIDNEY                                     | PANCREAS                            | LIVER                                 | HEART                                    | STOMACH                               | SMALL INTESTINE                       | DUODENUM                              | COLON                                 | LY MPH NODE                           | SPLEEN                                  | ADRENAL GLANT                          | TY ROID GLAND                          | SALIVARY GLAND                      | SKELETAL MUSCLE                  | BRAIN                                | COMMENT  |
|----------------------|-------|--------|---|---|---------------------------------------|---------------------------------------|--|--|--|--|--|--|--|---|--|-------------------------------------|---------------------------------------|--|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---|--|--|-------------------------------------|----------------------------------|--------------------------------------|--|
|                      |       | uCP    | 1<br>21<br>X<br>X<br>13                 | HSPG2<br>AGRN<br>COL18A1<br>GPC3<br>GPC4<br>GPC6                    | 116<br>7<br>25<br>12<br>64<br>22      | 31<br>15<br>36<br>9<br>3<br>3         | 140<br>14<br>35<br>150<br>16<br>20     | 62<br>18<br>38<br>23<br>20<br>40       | 20<br>4<br>99<br>32<br>45<br>27        | 51<br>23<br>56<br>16<br>23<br>23       | 16<br>21<br>26<br>18<br>29<br><b>5</b> | 72<br>15<br>49<br>28<br>47<br>9        | 63<br>16<br>37<br>1114<br>100<br>2     | 55<br>57<br>26<br>220<br>66<br>13       | 19<br>48<br>80<br>79<br>43<br>18           | 6<br>8<br>23<br>10<br>11            | 5<br>4<br>128<br>2<br>3<br>28         | 31<br>4<br>14<br>12<br>5<br>5            | 27<br>17<br>15<br>9<br>27<br>13       | 18<br>16<br>29<br>7<br>22<br>10       | 17<br>12<br>34<br>4<br>26<br>6        | 29<br>18<br>24<br>7<br>33<br>20       | 19<br>5<br>18<br>6<br>10<br>1         | 43<br>15<br>66<br>7<br>19<br>7          | 28<br>3<br>41<br>49<br>26<br>8         | 59<br>30<br>22<br>15<br>23<br><b>6</b> | 18<br>19<br>12<br>7<br>17<br>3      | 14<br>2<br>4<br>0.6<br>14<br>0.5 | 6<br>10<br>10<br>18<br>6<br>16       | Essential ubiquitous core<br>proteins (uCP)  |
| ESSENTIAL            | -     | uTetr  | 16<br>17<br>5<br>1<br>1<br>11<br>3      | XYLT1<br>XYLT2<br>B4GALT7<br>FAM20B<br>B3GALT6<br>B3GAT3<br>PXYLP1  | 19<br>21<br>10<br>69<br>16<br>20<br>9 | 13<br>22<br>22<br>38<br>17<br>38<br>6 | 10<br>9<br>10<br>48<br>16<br>17<br>4   | 11<br>15<br>11<br>53<br>15<br>27<br>10 | 26<br>24<br>16<br>69<br>19<br>38<br>13 | 8<br>26<br>16<br>51<br>17<br>44<br>13  | 8<br>32<br>17<br>28<br>10<br>37<br>19  | 14<br>21<br>13<br>82<br>23<br>42<br>14 | 20<br>23<br>15<br>53<br>21<br>48<br>17 | 6<br>16<br>14<br>68<br>22<br>34<br>6    | 2<br>11<br>14<br>14<br>11<br>14<br>14<br>7 | 1<br>13<br>28<br>32<br>4<br>21<br>2 | 0.5<br>3<br>4<br>19<br>6<br>8<br>3    | 3<br>13<br>13<br>29<br>8<br>9<br>5       | 7<br>33<br>9<br>35<br>13<br>27<br>4   | 12<br>10<br>9<br>30<br>9<br>27<br>6   | 9<br>9<br>10<br>24<br>8<br>26<br>6    | 11<br>17<br>13<br>36<br>10<br>16<br>5 | 16<br>19<br>36<br>17<br>65<br>11      | 15<br>21<br>18<br>40<br>24<br>52<br>8   | 34<br>12<br>12<br>65<br>12<br>30<br>5  | 9<br>20<br>17<br>74<br>24<br>39<br>9   | 2<br>10<br>13<br>17<br>6<br>18<br>4 | 0.6<br>3<br>11<br>3<br>2<br>0.8  | 9<br>13<br>19<br>43<br>9<br>20<br>12 | Essential ubiquitous GAG-CP<br>linker (uTetr)  |
|                      |       | cQ uHS | 8<br>8<br>11<br>5<br>15<br>1<br>2<br>20 | EXTL3<br>EXT1<br>EXT2<br>NDST1<br>GLCE<br>HS2ST1<br>HS6ST1<br>SULF2 | 32<br>100<br>58<br>19<br>22<br>19     | 41<br>80<br>24<br>21<br>35            | 11<br>16<br>43<br>55<br>17<br>15<br>25 | 17<br>35<br>58<br>42<br>21<br>28<br>62 | 16<br>23<br>71<br>59<br>38<br>35<br>46 | 13<br>22<br>56<br>36<br>16<br>25<br>35 | 23<br>12<br>50<br>56<br>13<br>25<br>58 | 22<br>28<br>97<br>36<br>23<br>32<br>25 | 24<br>1<br>122<br>36<br>32<br>18<br>36 | 14<br>34<br>52<br>119<br>24<br>25<br>33 | 7<br>10<br>29<br>27<br>22<br>17<br>49      | 3<br>4<br>15<br>16<br>4<br>5<br>13  | 3<br>15<br>17<br>32<br>17<br>14<br>11 | 21<br>10<br>19<br>28<br>6<br>7<br>7<br>7 | 7<br>15<br>33<br>16<br>16<br>14<br>13 | 6<br>41<br>48<br>31<br>48<br>20<br>25 | 6<br>45<br>34<br>22<br>29<br>16<br>16 | 7<br>28<br>41<br>27<br>27<br>19<br>22 | 9<br>13<br>31<br>19<br>10<br>31<br>20 | 16<br>24<br>44<br>124<br>12<br>31<br>69 | 24<br>17<br>36<br>53<br>29<br>53<br>54 | 18<br>28<br>73<br>86<br>15<br>35<br>25 | 6<br>5<br>24<br>41<br>12<br>7<br>13 | 6<br>1<br>4<br>9<br>2<br>2<br>11 | 24<br>3<br>6<br>21<br>9<br>18<br>31  | Essential ubiquitous HS (uHS)<br>elongation & sulfation  |
|                      | =     | g      | 20<br>10                                | HPSE2   | 199<br>4                              | 24<br>0.6                             | 34<br>1                                | 75<br>28                               | 214<br>nd                              | 33<br>19                               | 37<br>5                                | 202<br>15                              | 60<br>3                                | 26<br>5                                 | 33<br>2                                    | 7<br>nd                             | 28<br>nd                              | 15<br>nd                                 | 20<br>0.7                             | 21<br>9                               | 30<br>7                               | 46<br>6                               | 50<br>nd                              | 30<br>nd                                | 13<br>nd                               | 30<br>nd                               | 7<br>0.7                            | 4<br>nd                          | 8                                    | Likely NA/NS domains Essential tissue restricted QC  |
|                      | E     | uCP    | 2<br>2<br>8<br>1<br>20                  | GPC1<br>SDC1<br>SDC2<br>SDC3<br>SDC4                                | 5<br>116<br>186                       |                                       | 17<br>12<br>106<br>49<br>48            | 21<br>220<br>97<br>71<br>178           | 23<br>4<br>268<br>33<br>77             | 69<br>67<br>97<br>61<br>145            | 15                                     | 21<br>5<br>152<br>72<br>200            | 50<br>75<br>169<br>40<br>108           | 91<br>57                                | 8<br>114<br>67<br>10<br>284                | 7                                   | 8<br>249<br>227<br>15<br>636          | 33<br>1<br>40<br>19<br>344               | 36<br>19                              | 5<br>144<br>36<br>28<br>90            | 23<br>20                              | 8<br>109<br>44<br>24<br>200           | 2<br>7<br>24<br>46<br>30              |   | 35<br>43<br>58<br>190<br>140           | 9<br>73<br>666<br>31<br>135            | 11<br>25<br>12<br>13<br>126         | 34<br>nd<br>6<br>3<br>21         | 15<br>11<br>42<br>87<br>137          | Non-essentail ubiquitous<br>core proteins (uCP)  |
|                      |       | gc     | 1<br>8<br>4                             | EXTL2<br>SULF1<br>HPSE  | 26<br>119<br>4                        | 11<br>2<br>15                         | 12<br>22<br>4                          | 22<br>89<br>8                          | 38<br>35<br>9                          | 29<br>79<br>2                          | 22<br>25<br>6                          | 38<br>32<br>12                         | 47<br>8<br>5                           | 17<br>18<br>11                          | 11<br>12<br>2                              | 8<br>1<br>0.8                       | 17<br>2<br>2                          | 6<br>9<br>0.5                            | 8<br>4<br>4                           | 7<br>20<br>6                          | 7<br>13<br>3                          | 10<br>21<br>11                        | 8<br>16<br>11                         | 17<br>3<br>16                           | 43<br>5<br>8                           | 22<br>30<br>3                          | 6<br>2<br>4                         | 3<br>1<br>nd                     | 19<br>2<br>7                         | Non-essentail ubiquitous QC<br>(uCQ)   |
| IAL                  |       | rCP    | 7<br>13                                 | GPC2<br>GPC5  | 1<br>nd                               | 9<br>nd                               | 0.6<br>nd                              | 0.7<br>nd                              | 0.9<br>0.9                             | 1<br>nd                                | 19<br>16                               | 2<br>nd                                | 0.5<br>0.6                             | 0.6<br>3                                | nd<br>11                                   | nd<br>nd                            | nd<br>0.9                             | 0.9<br>0.5                               | nd<br>nd                              | 0.9<br>nd                             | 0.7<br>nd                             | 4<br>0.6                              | 3<br>nd                               | 2<br>nd                                 | 0.5<br>4                               | nd<br>1                                | 0.9<br>nd                           | nd<br>nd                         | 13<br>5                              | Non-essential tissue restricted<br>core proteins (rCP)   |
| <b>NON-ESSENTIAL</b> |       |        | X<br>13                                 | NDST2<br>HS6ST2<br>HS6ST3<br>HS3ST1                                 | 5<br>6<br>7<br>3                      | 6<br>0.5<br>nd<br>nd                  | 3<br>0.9<br>0.9<br>1                   | 3<br>6<br>18<br>12                     | 4<br>45<br>nd<br>61                    | 4<br>6<br>1<br>3                       | 4<br>8<br>1<br>3                       | 5<br>14<br>9<br>5                      | nd<br>35<br>nd<br>2                    | 6<br>1<br>nd<br>3                       | 1<br>21<br>2<br>2                          | 1<br>2<br>1<br>nd                   | 0.9<br>nd<br>nd                       | 0.8<br>nd<br>nd<br>nd                    | 2<br>nd<br>2<br>4                     | 2<br>nd<br>0.5<br>2                   | 2<br>nd<br>0.9<br>2                   | 2<br>2<br>nd<br>3                     | 7<br>nd<br>nd<br>3                    | 8<br>nd<br>nd<br>4                      | 3<br>6<br>nd<br>3                      | 4<br>0.6<br>6<br>1                     | 2<br>nd<br>nd<br>1                  | nd<br>3<br>nd<br>nd              | nd<br>1<br>40<br>2                   | Non-essential tissue restricted<br>sulfation (rHS)   |
|                      | N     | rHS    | 17<br>17<br>4<br>4                      | HS3ST2<br>HS3ST3A1<br>HS3ST3B1<br>NDST3<br>NDST4<br>HS3ST4          |                                       | 3<br>nd<br>nd                         | 4<br>nd<br>2<br>nd<br>nd               | 2<br>0.8<br>6<br>nd<br>1               | 9<br>7<br>12<br>nd<br>5                | 2<br>6<br>nd<br>0.6                    | 0.7<br>2<br>nd<br>0.9                  | 3<br>nd<br>0.6                         | 2<br>6<br>2<br>nd<br>nd                | 16<br>0.7<br>4<br>nd<br>nd              | nd<br>1<br>4<br>0,5<br>nd                  | nd<br>nd<br>0.9<br>nd<br>nd         | 1<br>0.9<br>36<br>1<br>nd             | 1<br>nd<br>1<br>nd<br>nd                 | 1<br>0.8<br>3<br>0.5<br>0.7           | 3<br>nd<br>nd                         | 3<br>nd<br>nd                         | 2<br>0.6<br>1<br>nd<br>nd             | 5<br>4<br>21<br>nd<br>nd              | 0.8<br>13<br>11<br>2<br>3               | 4<br>3<br>3<br>1<br>nd                 | 0.8<br>nd<br>2<br>nd<br>nd             | nd<br>nd<br>7<br>nd<br>nd           | nd<br>nd<br>nd<br>nd             | 20<br>nd<br>1<br>2<br>1              | 6-0-<br>оос °Сонюсо;<br>но то, соню со, сонюсо;<br>о, сонос;<br>о, сонюсо;<br>о, сонос;<br>о, сонос |
|                      |       |        | 6                                       | HS3ST4<br>HS3ST5<br>HS3ST6  |                                       | nd<br>0.7<br>108                      | nd<br>nd<br>nd                         | 0.6<br>0.7<br>5                        | nd<br>nd<br>nd                         | 3<br>nd<br>0.5                         | 1<br>0.5<br>0.6                        | nd<br>nd<br>nd                         | nd<br>nd<br>3                          | nd<br>0.8<br>0.7                        | nd<br>nd<br>nd                             | nd<br>nd<br>nd                      | nd<br>nd<br>0.8                       | nd<br>nd<br>nd                           | nd<br>nd<br>nd                        | nd<br>nd<br>nd                        | nd<br>nd<br>nd                        | nd<br>nd<br>0.6                       | nd<br>nd<br>nd                        | 5<br>nd<br>nd                           | nd<br>0.9<br>nd                        | nd<br>nd<br>nd                         | nd<br>nd<br>nd                      | nd<br>2<br>nd                    | 11<br>4<br>nd                        | N-<br>Likely NS domains<br>(Specialized HS sequences)  |
|                      |       | QC     | 1                                       | EXTL1   | 4                                     | 2                                     | nd                                     | 0.6                                    | 3                                      | 0.7                                    | 1                                      | 4                                      | 2                                      | nd                                      | nd   | nd                                  | nd                                    | 3  | nd                                    | nd                                    | nd                                    | nd                                    | 0.7                                   | 4                                       | 3                                      | 1                                      | nd                                  | 6                                | 7                                    | Non-essential tissue restricted QC   |
|                      | GENES | CE     |   | GAPDH<br>ACTB   |                                       | 1009<br>1375                          | 558<br>1836                            | 1741<br>4533                           | 686<br>2306                            | 974<br>2972                            | 768<br>1113                            | 739<br>5617                            | 1763<br>3463                           | 577<br>4197                             | 831<br>799                                 | 177<br>188                          | 600<br>1257                           | 1989<br>426                              |                                       | 1205<br>2521                          | _                                     | _                                     |                                       | 775<br>5164                             |  | 1105<br>2631                           | 532<br>846                          | 6797<br>176                      | 894<br>1545                          | >100 TPM<br>10-100 TPM<br>1-10 TPM<br>Selow cutoff   |

Fig. 4. The human HSPG biosynthetic machinery genes organized by gene essentiality and expression levels. HSPG biosynthetic genes were first separated in 'Essential' or 'Non-essential' for normal development and homeostasis depending on their requirement for normal human development and homeostasis and/or the phenotype of the corresponding gene null mouse (Suppl. Inf). Then, genes were re-clustered depending on their expression (transcript par million TPM) in a variety of human organs or tissues, as documented from RNAseq databases (FANTOM5: <a href="http://fantom.gsc.riken.jp/data/">http://fantom.gsc.riken.jp/data/</a>; ENCODE: <a href="https://www.encodeproject.org/">https://www.encodeproject.org/</a>; and 32Uhlen: <a href="http://www.proteinatlas.org/humanproteome/tissue+specific">http://fantom.gsc.riken.jp/data/</a>; ENCODE: <a href="https://www.encodeproject.org/">https://www.encodeproject.org/</a>; and 32Uhlen: <a href="http://www.proteinatlas.org/humanproteome/tissue+specific">http://www.proteinatlas.org/humanproteome/tissue+specific</a>). Genes were organized in 4 main groups depending on their basal expression levels in adult human. CQ stands for 'Quality Control' that can arrest HS elongation during synthesis or remodel HS structure after secretion to the extracellular space. Ion and nucleotide transporters coding genes are not included.

NDST399-101, and NDST4102,103), two HS6STs (HS6ST2104,105, HS6ST3106,107), all HS3STs 270 (HS3ST1<sup>108-110</sup>, HS3ST2<sup>111,112</sup>, HS3ST3A1<sup>113-115</sup>, HS3ST3B1<sup>115</sup>, HS3ST4<sup>116</sup>, HS3ST5<sup>117</sup>, and 271 272 HS3ST6<sup>118,119</sup>), and one HS levels regulating genes (EXTL1<sup>120</sup>). Based in current available data and 273 literature records, it appeared that, at least in the absence of instigating stimuli, these genes are non-274 causative of disease and are not essential for normal development and homeostasis (Supp. Inf). 275 Accordingly, their corresponding gene null mice, when available, develop normally, are fertile, and 276 show non deleterious phenotypes (Supp. Inf). Depending on the gene, mice can show inappropriate 277 response to instigating stimuli during processes including wound healing, angiogenesis, 278 inflammation, immunity, infection, and response to neurological stimuli leading to altered adaptative 279 behaviors (as alertness and satiety during feeding, and response to stress) (Suppl. Inf.). Moreover, 280 SNP in Group IV genes, along or in combination with SNP in other loci, have been associated to 281 vulnerability or resistance to diseases, to infection, and to impaired angiogenesis, inflammation, 282 immunological response, altered behaviors, etc. (Fig. 3 and Suppl. Inf.). It is to note that all the HS 283 sulfotransferases coding genes that did not cluster in Group I clustered in this group, including 284 NDST2, HS6ST2, HS6ST3, and all HS3STs. Thus, based in information from knockout mice, GWAS 285 data, and literature research, it appeared that the tissue restricted rHS sequences are those required 286 for appropriate adaptive behaviors and responsiveness to stimuli in tissues in which each gene is 287 specifically expressed.





### **3.3.** Functional aspects of the HSPG core proteins

#### 300 **3.3.1. Essential pericellular core proteins**

301 Pericellular HSPG are essential constituents of basement membranes, the highly specialized 302 extracellular matrices that tie the epithelium to connective, endothelial, muscular, neuronal, and other 303 tissues<sup>121</sup>. The main pericellular HSPG core proteins are perlecan, agrin, and collagen 18, 304 respectively coded by HSPG2, AGRN, and COL18A1, which clustered in Group I (Table 1, Fig. 5, 305 and Suppl. Inf.). Perlecan is mainly expressed in skeletal, musculoskeletal, and cardiovascular basement membranes<sup>23,122</sup>. Hence, *HSPG2* variants affect these tissues with severities that depend 306 307 on the variant, as observed in Stuve-Wiedemann, Schwartz-Jampel and lethal Kniest-Like syndromes<sup>23,25</sup>, which traits are recapitulated in the Hspg2<sup>-/-</sup> mouse<sup>22</sup>. Similarly, clinical variants in 308 309 AGRN, which codes for the agrin core protein characteristically expressed in neuromuscular 310 junctions<sup>122</sup>, result in a myasthenic syndrome, recapitulated in the Agrn<sup>-/-</sup> mouse<sup>27,29</sup>. Collagen XVIII additionally supports basement membranes in some tissues<sup>32</sup>, as suggested by the traits observed 311 312 in COL18A1 variants that lead to eye defects, occipital encephalocele (Knobloch syndrome), and 313 other overt phenotypes recapitulated in the *Col18a1*<sup>-/-</sup> mouse<sup>30,31</sup>. In addition to the importance of 314 pathogenic variants, SNP has been associated with risk to altered health condition or disease (Table 315 1, Fig. 3). For instance, HSPG2 SNP has been associated with tardive dyskinesia<sup>123</sup> whereas 316 COL18A1 SNP has been associated with pelvic organ prolapse<sup>124</sup>. Globally, these data confirm the 317 essentialness of ubiquitous pericellular HSPG core proteins, and the importance of their likely-318 ubiquitous HS chains, in the pericellular matrix organization<sup>1</sup>.

### 319 **3.3.2.** Essential cell membrane-associated core proteins

320 Among HSPG membrane-associated core proteins coding genes, only GPC3, GPC4, and GPC6 321 clustered in Group I (Table 1, Fig. 5, and Supp. Inf.). By keeping the HS chains very close to cell 322 membranes, glypicans are known to bring HS binding proteins near to their high affinity receptors<sup>125</sup>. 323 Proteins requiring this proximity includes fibroblast growth factors, bone morphogenetic proteins, wints, hedgehogs, and several other proteins involved in cell signaling<sup>125</sup>. Among *GPCs* pathogenic 324 325 variants, those in GPC3 are the most severe, as shown by pre- and post-natal overgrowth with 326 skeletal, visceral, and neurological abnormalities observed in the X-linked Simpson-Golabi-Behmel syndrome resulting from GPC3 variability<sup>34</sup> and recapitulated in the Gpc3<sup>-/-</sup> mice<sup>33</sup>. Similar traits are 327 328 observed in GPC4 variants responsible of Keipert syndrome<sup>36</sup>, characterized by craniofacial and 329 digital abnormalities, deafness, and synaptic impairment, and in GPC6 variants responsible of 330 omodysplasia-1<sup>37</sup> with facial dysmorphism, short stature, and shortened limbs, recapitulated in the knockout mice<sup>39</sup>. In addition to pathogenic genetic variability, SNP in GPC4 and GPC6 has been 331 332 associated to risk to altered conditions (Table 1 and Suppl. Inf). These data confirm the essentialness 333 of the ubiquitous GPC3, GPC4, GPC6 in normal development and homeostasis and suggest that

### 334 Table 1. Genes coding for ubiquitous and tissue restricted HSPG core proteins. Genes are organized

based on their expression in human tissues and traits of their clinical variants and/or phenotype of null mice.

|  | Gene    | Impact of genetic variants<br>in human  | Phenotype of the null mouse   | Most affected<br>organs or tissues   | Ref.                 |
|--|---------|---|---|--|----------------------|
|  | HSPG2   | From mild to lethal diseases: Lethal Kniest-<br>like syndrome, Schwartz Jampel syndrome<br>type 1, Stuve-Wiedemann syndrome,<br>dyssegmental dysplasia of Silverman-<br>Handmaker type (various degrees of bone<br>dysplasia, cardiovascular and pulmonary<br>defects, myotonia, hyperthermia). SNP<br>associations with tardive dyskinesia and<br>intracranial aneurysm. | Embryonic lethality (E10-12) with<br>severe chondrodysplasia, defective<br>skeletal and cephalic development.   | Cartilage, bone,<br>bone marrow,<br>cardiac muscle,<br>brain, vasculature,<br>etc. | 22-25,<br>123        |
| sed  | AGRN    | Congenital myasthenic syndrome with distal<br>muscle weakness and atrophy with or<br>without synaptic dysfunction. SNP<br>associations with myasthenia gravis.  | Embryonic lethality or die at birth due<br>to respiratory failure, altered growth<br>plate, central nervous system defects,<br>and other defects.   | Neuromuscular<br>junctions, muscle,<br>brain, growth plate.                        | 26,27,<br>29,126     |
| GROUP I<br>Essential<br>Widely expressed           | COL18A1 | Knobloch syndrome (severe eye and encephalocele defects). SNP association with pelvic organ prolapse.   | Viable but with defects in the<br>vasculature, ocular tissue, kidney<br>proximal tubules, heart valves,<br>epidermis, choroid plexus.   | Eyes, kidney, heart,<br>vasculature, brain,<br>and epidermis.                      | 30-<br>32,124<br>127 |
| 5  | GPC3    | Simpson-Golabi-Behmel syndrome<br>(pre/post-natal overgrowth, skeletal, facial,<br>visceral, neurological anomalies). Wilms<br>tumor (nephroblastoma).  | Perinatally die with kidney and lung<br>dysplasia, cystic kidneys, etc.<br>Recapitulates Simpson-Golabi-<br>Behmel syndrome.  | Bone, brain, kidney,<br>lung, muscle, etc.   | 33,34                |
|  | GPC4    | Keipert Syndrome (craniofacial and digital<br>abnormalities, cognitive impairment,<br>deafness, etc.). SNP association with autism<br>spectrum disorders.   | Craniofacial and digital abnormalities, behavioral alterations.   | Brain, cranial bone,<br>limb, hearing.   | 36,37                |
|  | GPC6    | Omodysplasia (facial dysmorphism, short<br>stature, shortened limbs). SNP association<br>with osteoporosis and multiple sclerosis.  | Die at birth with severe facial dysmorphism and short bones.  | Skeleton, facial<br>bones.   | 38-40                |
|  | GPC1    | No pathogenic variants reported.<br>SNP association with risk of schizophrenia<br>and biliary atresia.  | Viable, fertile, healthy. However, slightly reduced brain size.   | Brain.   | 80,81,<br>129        |
| σ  | SDC1    | No pathogenic variants reported.<br>SNP association with risk of coronary plaque<br>in patients with coronary artery disease and<br>risk of biliary atresia.  | Viable, fertile, and healthy.<br>However, altered response to stimuli<br>during wound healing, inflammation,<br>fibrosis, re-vascularization, infection   | Several tissues,<br>altered response to<br>instigating agents<br>and angiogenesis. | 69,70,<br>130        |
| GROUP III<br>Non-essential<br>Widely expressed     | SDC2    | No pathogenic variants reported.<br>SNP association with risk of posttraumatic<br>stress disorder.  | Mouse has not been generated.<br>However, altered adaptative<br>responses during tissue recovery after<br>injury (fibrosis, inflammation).  | Several tissues,<br>altered response to<br>instigating agents<br>and angiogenesis. | 72,130<br>132        |
| O<br>Noi<br>Wide                                   | SDC3    | No pathogenic variants reported.<br>SNP association with resistance to obesity<br>and risk to metabolic syndrome and female<br>hyperandrogenism.  | Viable, fertile, and healthy.<br>However, altered resistance to obesity<br>and altered feeding behavior.  | Brain, immune and<br>adrenal systems.  | 73-76,<br>130,13     |
|  | SDC4    | No pathogenic variants reported.<br>SNP association with miss-regulation of<br>whole-body energy metabolism and with<br>longevity and lipid profile in healthy elderly.   | Viable, fertile, and healthy life.<br>However, altered reactivity to stimuli<br>related to wound healing.   | Several tissues:<br>altered response to<br>instigating agents<br>and angiogenesis. | 77,79,<br>134        |
| GROUP IV<br>Non-essential<br>Restricted expression | GPC2    | No pathogenic variants reported.<br>SNP as part of polygenic risk suggestive of<br>Alzheimer's disease.   | Mouse has not been generated.<br>However, transcript and protein levels<br>increase when neurogenesis is<br>stimulated in the adult mice brain and<br>decrease when neurogenesis is<br>ablated. | Brain.   | 91,128               |
|  | GPC5    | No pathogenic variants reported.<br>SNP association with risk for multiple<br>sclerosis, autoimmune thyroid disease, and<br>acquired nephrotic syndrome.  | Mouse has not been generated.   | Kidney and testis.   | 93-95                |

glypican, at least glypicans 3, 4 and 6, are the main HSPG that carry the HS involved in essentialcell signaling. Whether these HS are made by the also ubiquitous HS biosynthetic genes is unknown.

#### 338 **3.3.3.** Non-essential cell membrane-associated HSPG core proteins

339 Excepting the essential GPC3, GPC4, GPC6, all other cell membrane-associated core proteins 340 coding genes (GPC1, GPC2, GPC5, SDC1, SDC2, SDC3, and SDC4) clustered in Groups III and 341 IV, both characterized for being non-essential for normal development but required for appropriated 342 response to stimuli, as during wound healing, angiogenesis, inflammation, immune response, normal behaviors, etc. (Table 1, Fig. 5, and Supp. Inf.). For instance, SNP in GPC1 loci was associated to 343 344 biliary atresia<sup>80</sup> and schizophrenia<sup>81</sup>, whereas GPC2, expressed in brain (Fig. 4) was involved in 345 proper response to neurogenic stimuli<sup>91</sup>. Similarly, the kidney, testis, and adrenal and thyroid glands predominant GPC5 (Fig. 4) was involved in podocyte response to injury and nephropathy 346 progression in type 2 diabetes patients<sup>135</sup> and SNP was associated with acquired nephrotic 347 syndrome, autoimmune thyroid disease, and risk for multiple sclerosis<sup>93-95</sup>. Similarly, syndecans are 348 required for appropriate tissue response to inflammation, infection, wound healing, angiogenesis, 349 350 neurological stimuli, etc.<sup>136-138</sup>. In agreement with the role of SCD genes in appropriate response to stimuli, the Sdc1<sup>-/-</sup> mouse showed altered capacity to recover from microbial infection or ischemia<sup>139</sup> 351 352 and the  $Sdc4^{-}$  mouse showed delayed wound healing and impaired angiogenesis<sup>134</sup>. Although the 353 Sdc2<sup>-/-</sup> mouse has not yet been generated, syndecan 2 has been involved in fibrosis and inflammation<sup>131,132</sup>. Moreover, SNPs in some of these genes have been associated with risk to 354 355 develop diseases involving altered adaptative behaviors. For instance, SDC1 polymorphism has 356 been associated with coronary plaque formation in coronary artery disease patients<sup>69</sup>, with multiple 357 sclerosis<sup>70</sup>, and with renal malfunction in adolescents with excess weight<sup>71</sup>. SDC2 polymorphism has 358 been associated to posttraumatic stress disorders in post war veterans<sup>72</sup>. SDC3 polymorphism has 359 been associate to satiety dysregulation and obesity<sup>74,76</sup>, metabolic syndromes<sup>73</sup>, and 360 schizophrenia<sup>75</sup>. SDC4 polymorphism was associated with risk of metabolic syndromes and obesity<sup>77</sup> 361 and with longevity in healthy elderly Italian<sup>79</sup>. Together, these data indicate that Group III and IV core 362 proteins, and possibly their HS chains, are required for appropriate responsiveness to stimuli and adaptative behaviors rather than for the regulation of essential physiological processes. 363

## **364 3.4. The GAG-CP-linker tetrasaccharide pathway first assures HSPG over CSPG**

### 365 biosynthesis

After synthesis of the core protein, the GAG-CP linker tetrasaccharide (Fig. 1) is synthetized by an ubiquitous biosynthetic machinery involving several genes which, with exception of XYLT1 and XYLT2<sup>3</sup>, have not paralogue genes able to assure compensation. Because this machinery is common to HSPG and CSPG, it can then be expected that defects in any of the ubiquitous GAG-CP

linker biosynthetic genes will affect production of both proteoglycans in all tissues. However, a
skeletal phenotype predominantly affecting CS is mainly observed in linkeropathies, the family of
diseases caused by variability in GAG-CP linker biosynthetic genes<sup>140</sup>. Here, the integrative analysis
of clinical variants, gene expression, enzymes selectivities, and protein clusters data (Table 2, Fig.
and Supp. Inf.) indicates that the GAG-CP linker biosynthetic pathway is organized to
preferentially assure production of HSPG over that of CSPG (Fig. 6A), as detailed below.

#### 376 **3.4.1.** The GAG-CP linker biosynthetic machinery

377 Biosynthesis of GAG-CP linker is initiated by addition of a xylose (Xyl) from UDP-Xyl to specific 378 serine residues in core proteins (Ser-CP)<sup>2,3</sup>. This is assured by XYLT1 during development and by 379 both XYLT1 and XYLT2 after bird<sup>42</sup> (Fig. 6A and Supp. Inf.). During development, XYLT1 is highly 380 expressed by chondroblasts<sup>42</sup>, the cells that secrete a CSPG aggrecan rich matrix that forms the cartilage template upon which bone is formed<sup>141</sup>. Indeed, as endochondral ossification of the 381 382 cartilage elements ensues, the expression of aggrecan by differentiating chondrocytes predominates 383 over expression of other proteoglycan core proteins<sup>142</sup>. Thus, to assure all proteoglycans 384 glycosylation in this high aggrecan content, XYLT1 binds to aggrecan core protein with lower affinity than to other core proteins<sup>41,143</sup>, including to the small leucine rich (SLRP) CSPG decorin that 385 386 stabilizes collagen fibrils in soft tissues, as skin and cornea<sup>144</sup>. The higher affinity of XYLT1 for 387 decorin over aggrecan splits the GAG-CP linker biosynthetic pathway in a CSPG-decorin path and 388 a HSPG/CSPG-aggrecan path (Fig. 6A), in which rich aggrecan synthesis is assured by an abundant 389 substrate pool. Thus, during development, a defective XYLT1 should primarily assure the decorin 390 path, principally affecting the CSPG-aggrecan path. Accordingly, XYLT1 variability results in 391 Desbuquois dysplasia type 2 (known as Baratela–Scott syndrome)<sup>41</sup>, characterized by severe 392 skeletal growth retardation with multiple dislocations, joint laxity, advanced carpal ossification, with 393 no skin overt phenotypes, indicating that the CSPG-decorin path is unaffected (Table 2 and Supp. 394 Inf.). After birth, under physiologic conditions, XYLT1 expression decreases and XYLT2 is 395 expressed. XYLT2 shows similar affinity for both decorin and aggrecan core proteins, possibly 396 because after birth the abundant aggrecan synthesis is not any more required and HSPG and CSPG 397 syntheses need to be balanced. Although at different extents depending on the tissue, both XYLT1 398 and XYLT2 are expressed after birth (Fig. 4), Thus, defects in XYLT2 should not affect development 399 and after birth they might be compensated by XYLT1, at least in some extent and in the tissues in 400 which the enzyme is expressed. Accordingly, during development XYLT2 variants show no clinical 401 significance, but after birth they cause the post-developmental spondyloocular disorder 402 characterized by osteoporosis, cataract, hearing, and learning impairment<sup>43,135</sup>.

403 On the continuation of the GAG-CP linker biosynthesis, B4GALT7 adds galactose (Gal) to Xyl-(Ser404 CP)<sup>145</sup> (Fig. 6A). B4GALT7 shows similar affinity for aggrecan and decorin core proteins, indicating
405 that defective B4GALT7 should affect both CSPG-decorin and HSPG/CSPG-aggrecan paths.
406 Accordingly, *B4GALT7* variants lead to B4GALT7-related Ehlers-Danlos syndrome

- 407 (spondylodysplastic EDS type 1)<sup>45</sup>, which traits are like those caused by *XYLT1* mutations (CSPG408 aggrecan path affected) with additional soft tissues overt phenotypes including hyperextensible, soft,
  409 thin, translucent, and doughy skin (CSPG-decorin path is affected) (Table 2 and Supp. Inf.)<sup>45</sup>.
- 410 Table 2. Ubiquitous GAG-CP linker tetrasaccharide biosynthetic genes. Genes are organized based on
- 411 their expression in human tissues and traits of their clinical variants and/or phenotype of null mice.

|  | Gene    | Impact of genetic variants<br>in human   | Phenotype of<br>the null mouse  | Most affected<br>organs or tissues   | Ref.          |
|--|---------|--|---|--|---------------|
|  | XYLT1   | Desbuquois dysplasia (DBQD) type 2<br>(also known as Baratela–Scott<br>syndrome), characterized by with short<br>stature, joint laxity, advanced carpal<br>ossification, mental retardation.                               | Non-available. However, a mouse<br>carrying a <i>Xylt1</i> mutation shows<br>chondrocyte premature<br>maturation, early ossification,<br>and dwarfism.  | Connective and<br>skeletal tissue,<br>brain.   | 41,42         |
|  | XYLT2   | Spondyloocular syndrome (post-<br>developmental osteoporosis, cataract,<br>hearing and learning impairment).   | Develops normally but show post-<br>developmental defects in liver,<br>biliary epithelial and renal cysts,<br>low body weight, adipose tissue<br>loss and lipodystrophy.                      | Skeletal, adipose,<br>and connective<br>tissues, liver, eye,<br>bone, brain, kidney. | 43,135<br>147 |
|  | B4GALT7 | Spondylodysplastic Ehlers-Danlos<br>Syndrome (spEDS)-progeroid type<br>(connective and skeletal tissues with<br>radioulnar synostosis) and Reunion<br>Island Larsen-like syndrome (large<br>spectrum).                     | Not reported.   | Bone, cartilage, skin,<br>brain, eye.  | 44,45,<br>148 |
| l<br>al<br>essed                         | FAM20B  | Short limb dysplasia resembling XYLT1-<br>related DBQD with mid-face and<br>thoracic hypoplasia (leading to<br>respiratory failure), very short stature,<br>mesomelic limbs shortening and<br>multiple joint dislocations. | Dies as embryo and shows<br>severely stunted growth,<br>multisystem organ hypoplasia,<br>and delayed development of the<br>skeletal system, eyes, lung,<br>gastrointestinal tract, and liver. | Multiorgan<br>hypoplasia, delayed<br>growth and<br>development.                      | 49,149<br>150 |
| GROUP I<br>Essential<br>Widely expressed | B3GALT6 | spEDS progeroid type 2 (affecting<br>connective and skeletal systems with<br>sever skeletal affections),<br>spondyloepimetaphyseal dysplasia with<br>joint laxity, learning defects.                                       | Not reported.   | Bone, cartilage, skin<br>tendons, ligaments,<br>brain.                               | 46,47         |
|  | B3GAT3  | Larsen-like syndrome with variable<br>phenotypes similar to Antley-Bixler,<br>Shprintzen-Goldberg, and Geroderma<br>osteodysplastica syndromes.  | Embryonic lethality before the 8-<br>cell stage because failed<br>cytokinesis.  | Bone, cartilage, skin<br>tendons, ligaments,<br>heart, brain.                        | 48            |
|  | CANT1   | Various skeletal phenotypes related to<br>DBQD and Larsen syndrome with growth<br>retardation, short extremities,<br>progressive scoliosis, joint laxity, severe<br>prenatal and postnatal growth<br>retardation, etc.     | Shows the continuum of skeletal<br>dysplasia phenotypes including<br>Desbuquois dysplasia and<br>multiple epiphyseal dysplasia.   | Skeletal and<br>connective tissues,<br>brain.  | 8,151         |
|  | SLC10A7 | Shortened long bones, growth plate and tooth enamel anomalies.   | Short stature, amelogenesis<br>imperfecta, and skeletal dysplasia<br>with scoliosis.  | Skeletal and connective tissues, brain.  | 10            |
|  | PXYLP1  | No pathogenic variants reported<br>possibly because lethal.<br>SNP association with good prognosis in<br>cancer immunotherapies.   | Not reported.   | Unknown  | 152           |


412

413

414

415 In the HSPG/CSPG-aggrecan path, the resultant Gal-Xyl-(Ser-CP) is then phosphorylated by FAM20B to form Gal-Xyl(P)-(Ser-CP) (Fig. 6A), which is the preferred B3GALT6 substrate that 416 417 additionally promotes the HSPG/CSPG-aggrecan path. Indeed, in further steps of the GAG-CP linker 418 synthesis, phosphorylated products will become the preferred substrates that nourish the HSPG 419 path<sup>49,146</sup>. This is consistent with the high lethality observed in the rare *FAM20B* clinical variants, 420 which show a phenotype like that observed in XYLT1-Desbuquois dysplasia (CSPG-aggrecan path is affected) but additionally affecting many other organs<sup>49</sup> (HSPG path is affected) (Fig. 6A). In the 421 422 next step of the GAG-CP synthesis, B3GALT6 transfers a second Gal to Gal-XyI(P)-(Ser-CP) in the HSPG/CSPG-aggrecan path and to Gal-Xyl-(Ser-CP) in the CSPG-decorin path<sup>145</sup>, nourishing both 423 424 pathways (Fig. 6). Again, the phosphorylated product is the preferred B3GAT3 substrate that will 425 then favor the HSPG path over the CSPG-aggrecan and CSPG-decorin paths (see below). 426 Accordingly, B3GALT6 mutations lead to B3GALT6-related spondylodysplastic Ehlers-Danlos 427 syndrome (spEDS), characterized by bone dysplasia, joint laxity (CSPG-aggrecan path is affected), 428 and mild skin hyper elasticity<sup>47</sup> (CSPG-decorin path is affected) (Table 2). Subsequently, depending 429 on substrate pool levels, B3GAT3 will act alone or in association with PXYLP1, for which it shows a 430 high affinity. Indeed, when complexed to PXYLP1, for which B3GAT3 shows the high affinity, GlcA 431 addition occurs followed by immediate Xyl dephosphorylation to form GlcA-Gal-Gal-Xyl-(Ser-CP), which is the preferred substrate for EXTL3 that starts HS chain initiation<sup>7,146,153</sup> (Fig. 6A and 6B). 432 433 Abundance of GIcA-Gal-Gal-Xyl-(Ser-CP) substrate pool allows CSGALNACT1 action on substrates 434 that did not integrate the HS path. Moreover, in associating with B3GAT3 un-complexed PXYLP1, 435 CSGALNACT1 can also act in Gal-Gal-Xyl(P)-(Ser-CP), which is the preferred substrate for CSGALNACT1, starting CS chain initiation<sup>7,146,153</sup>. Thus, higher expression levels of B3GAT3 436 437 compared to PXYLP1 (Fig. 4) and high affinity between PXYLP1 and B3GAT3 can favor equilibrium 438 through the HS synthesis. PXYLP1 un-complexed B3GAT3 (Fig. 6A). Therefore, in defective EXTL3, 439 its substrate excess allows the initiation of CS chain synthesis by CSGALNACT1 along or in 440 association with PXYLP1<sup>146,153</sup>, favoring aggrecan synthesis (Fig. 6A and 6B)<sup>7,146,153</sup>. Thus, the 441 phosphorylated and non-phosphorylated substrate pools and the levels of expression of B3GAT3, 442 PXYLP1, XYLT3, and CSGALNACT1, at least, will participate to the selection of the proteoglycan 443 that will be preferentially elongated<sup>146</sup>. Globally, based in literature data, clinical variants and 444 expression databases, our analysis indicate that the CSPG and HSPG overlapping paths can 445 concomitantly occur with crossed pathways, which preferences are driven by abundancy of 446 substrates pools, substrates selectivities, levels of expression, and protein-protein interactions. In 447 case of defective genes, the preferred maintain of the HSPG path is supported by the mixed skeletal and soft tissue phenotypes observed in B3GAT3 clinical variants responsible of Larsen, Antley-448 Bixler, Shprintzen-Goldberg, Geroderma osteodysplastica, and spEDS<sup>48</sup> and other linkeropathies 449 450 (Tables 2 and 3).

451



452 Fig. 6. Schematic representation of the HSPG biosynthetic pathway. The HSPG path (brown arrows) overlaps 453 with the CSPG-aggrecan path (marine blue arrows). The CSPG-decorin path (light blue arrows) is spliced from 454 HSPG/CSPG path at early steps. Black arrows designate paths that stop GAG elongation. Arrow width designs 455 preferred paths based in substrate preferences (see Gene review), wider arrows indicating preferred paths. 456 Substrate pools guarantees maintenance of minor paths (narrow arrows). Dotted arrows indicate non-detailed 457 steps. Green empty arrows indicate UDP-sugars or ion transport. Some nucleotide transporters or ion transports are represented. lons as Ca<sup>2+</sup>, Mn<sup>2+</sup> and/or Mg<sup>2+</sup> are indicated when required for enzymatic activity. A) Biosynthesis 458 459 of the GAG-CP linker tetrasaccharide common to HSPG and CSPG. ), Excepting XYLT1 and XYLT2, all enzymes 460 and transports are ubiquitously expressed during development (dev) and after birth (aft. birth). XYLT1 is highly 461 expressed during development (11dev) and its expression decreases aft. birth and preferentially binds to low 462 molecular weight CSPG core proteins, as decorin (leading to favored CSPG-decorin path), XYLT2 is expressed aft. 463 birth and shows similar binding to HSPG and CSPG core proteins (leading to both CSPG-decorin and HSPG/CSPG-464 aggrecan paths). Xyl is not phosphorylated in the CSPG-decorin path. B) Ubiquitously expressed enzymes drive 465 the synthesis of ubiquitous HS sequences (uHS). C) Tissue restricted enzymes form HS sequences (rHS) likely 466 during response to stimuli. rHS might contain high NS domains formed either from uHS or directly from unsulfated 467 chains). D) Representative HS disaccharide indicating GlcA, IdoA and GlcN units and sulfation positions (in red).

#### 468 **3.4.2.** Other enzymes and transporters

469 In addition to variability in GAG-CP linker biosynthetic genes, genetic variability in ion and nucleotide 470 transporters, or in other Golgian proteins that allow availability of sugar nucleotides and ions, can dramatically alter the biosynthesis of the GAG-CP linker<sup>154,155</sup>. For instance, the calcium activated 471 472 nucleotidase-1 (CANT1) hydrolyses the uridine diphosphate nucleoside (UDP), which inhibits glycosyltransferases (as XYLTs)<sup>155</sup> (Fig. 6A). Accordingly, CANT1 clinical variants lead to 473 Desbuquois dysplasia traits like those observed in XYLT1 and B4GAT7 variants<sup>8,151</sup> (Table 2). 474 Because CANT1 is calcium dependent, variants in the Ca<sup>2+</sup> transporter SLC10A7 result in skeletal 475 dysplasia with CANT1 and XYLT1 overlapping traits<sup>10</sup> (Table 2). Similarly, variants in genes coding 476 for sulfate ion transporters (SLC26A2)<sup>156</sup>, nucleotide (UDP-GlcNAc and UDP-Gal) transporters 477 478 (SCL35A2 and SCL35A3), or ions ( $Mq^{2+}$  and  $Mn^{2+}$ ) transporters required for proper enzymatic activities at the Golgi (Fig. 6A), can result in linkeropathies-like phenotypes<sup>9,155,157</sup>. 479

### 480 **3.5.** Essential and non-essential HS sequences

#### 481 **3.5.1.** Ubiquitous HS are essential for normal development and homeostasis

482 After biosynthesis of the GAG-CP linker, formation of the HS chain starts by the action of the 483 glycosyltransferase EXTL3<sup>2</sup>, which adds a GlcNAc residue to the dephosphorylated GlcA-Gal-Gal-484 Xyl-(Ser-CP) product of B3GAT3/PXYLP1 (Fig. 6B). EXTL3 deficiency results in reduced HSPG and 485 increased CSPG levels, confirming that abundant GlcA-Gal-Gal-Xyl-(Ser-CP) and GlcA-Gal-Gal-486 Xyl(P)-(Ser-CP) substrate pools respectively favor CSGALNACT1 and CSGALNACT1/PXYLP1 activities, thus driving CS initiation (Fig. 6A). Accordingly, lack of Ext/3 in mice causes embryonic 487 488 lethality possibly due to the lack of HS chain synthesis. In human, biallelic mutations in 489 the *EXTL3* gene result in a neuro-immuno-skeletal dysplasia syndrome<sup>54</sup>, suggesting an imbalanced 490 HSPG/CSPG-aggrecan paths with decreased HS synthesis and increased syntheses of CSPG 491 aggrecan and neurocan (Fig. 6A and 6B, Table 3, and Supp. Inf.). Following continuation of the HS 492 chain synthesis, the EXT1/EXT2 hetero-oligomeric complex elongates the HS chain by alternated 493 addition GlcNAc and GlcA to the GlcNAc-GlcA-Gal-Gal-Xyl-(Ser-CP) substrate, which initiates HS 494 chain elongation<sup>2</sup> (Fig. 6B). In *Ext1/Ext2* depleted mice, lack of HS leads to gastrulation failure and 495 embryonic death<sup>55,56</sup>, agreeing the essentialness of HS chains carried by proteoglycans. In human, 496 EXT1 or EXT2 variants lead to hereditary multiple exostoses (Table 3), characterized by the 497 formation of cartilage-capped bony outgrowths<sup>158</sup>, suggestive of the accumulation of EXT1/EXT2 498 GlcNAc-GlcA-Gal-Gal-Xyl-(Ser-CP) substrate, which is the EXTL3 product. Thus, this in turn results 499 in increased GlcA-Gal-Gal-Xyl-(Ser-CP) pool, which nourishes the CSPG-aggrecan path (Fig. 6A). 500 Thus, in the context of GlcA-Gal-Gal-Xyl-(Ser-CP) substrate pool excess, CSPG-aggrecan can be 501 accumulated in tissues in which its synthesis is rich, explaining the epiphyseal growth plates resulting 502 in cartilage-capped bony outgrowths. On the continuation of HS elongation, HS chain maturation is 503 assured by the ubiquitous NDST1, HS2ST, HS6ST1, and C5-epimerase (GLCE), which respectively 504 assure basal N-deacetyl-N-sulfation, 2-O-sulfation, 6-O-sulfation, and GlcA/IdoA epimerization<sup>2</sup>. 505 Interestingly, NDST1 and HS6ST1 substrate specificities suggest that, in association with HS2ST and GLCE, these enzymes can form sequences carrying NA/NS domains<sup>59,159-163</sup> (Supp. Inf.). 506 507 Indeed, NDST1 can generate HS domains with lower level of *N*-sulfation than NDST2<sup>164</sup> while 508 HS6ST1 shows higher selectivity for non-2-O-sulfated residues (hexA-GlcNS), as confirmed in the 509 Hs6st1 null mouse<sup>59</sup>. According with their essentialness, uHS made of NA/NS domains might then 510 be those that interact and regulate HBP required for normal development and homeostasis<sup>17,165</sup>. Accordingly, Ndst1<sup>-/-</sup>, Hs2st1<sup>-/-</sup>, and Glce<sup>-/-</sup> mice perinatally die with severe developmental 511 512 abnormalities<sup>57,60,61</sup>, and the *Hs6st1<sup>-/-</sup>* mouse cannot thrive<sup>59</sup> (Table 3).

513 **Table 3. Ubiquitous heparan sulfates (uHS) biosynthetic genes.** Genes are organized based on their 514 expression in human tissues and on clinical variants traits and/or phenotype of the corresponding null mice.

|  | Gene   | Impact of genetic variants<br>in human   | Phenotype of the null mouse  | Most affected<br>organs or tissues  | Ref.          |
|--|--------|--|--|---|---------------|
|  | EXTL3  | Severe autosomal recessive skeletal<br>dysplasia, including epispondylo-<br>metaphyseal dysplasia, with<br>developmental delay, immunodeficiency,<br>and neuromotor and brain development<br>delay.  | Embryonically lethal at around 9<br>days post-fecundation with HS<br>non-detected and with over<br>production of CS in chondrogenic<br>tissues.  | All tissues.  | 54,167        |
|  | EXT1   | Hereditary multiple exostoses (multiple<br>cartilaginous tumors), scoliosis, seizures,<br>macrocephaly, defects in pancreas, lung,<br>heart, cornea, etc.  | <i>Ext1<sup>-/-</sup>Ext2<sup>-/-</sup></i> mice die at embryo due to gastrulation failure. <i>Ext1<sup>-/-</sup></i> form several exostoses.  | Cartilage and bone.   | 55,158        |
|  | EXT2   | Hereditary multiple exostoses (less severe that that caused by EXT1).  | <i>Ext1<sup>-/-</sup>Ext2<sup>-/-</sup></i> mouse dies at<br>embryo due to gastrulation<br>failure. <i>Ext1<sup>-/-</sup></i> mouse forms<br>several exostoses.  | Cartilage and bone.   | 55,56,<br>158 |
| GROUP I<br>Essential<br>Widely expressed | NDST1  | Compound heterozygous mutations cause<br>developmental delays, muscular<br>hypotonia, ataxia, history of seizures,<br>intellectual disability, epilepsy,<br>gastroesophageal reflux, minor<br>malformation, etc. Partially compensated<br>by NDST2 except in brain (expressing<br>NDST3 and 4), and skeletal muscle. | Ndst1 <sup>-/-</sup> perinatally dies by<br>respiratory failure and shows<br>skeletal, brain, and heart defects.<br>Heterozygous mouse shows<br>severe developmental defects of<br>the forebrain and forebrain-<br>derived structures. | Brain, lung, skeletal<br>and hearth muscles,<br>stomach, etc.                                   | 58,61         |
|  | GLCE   | No pathogenic variants reported possibly<br>because lethal.<br>SNP associations with hypertension, and<br>cerebrovascular events.  | Neonatally lethal with severe<br>developmental abnormalities on<br>kidney, lung, skeleton, spleen,<br>thymus, lymph node, etc.   | Several organs:<br>kidney, skeleton,<br>thymus, lung, lymph<br>node, spleen, etc.               | 11,57,<br>168 |
|  | HS2ST1 | No pathogenic variants reported possibly<br>because lethal.<br>SNP has been associated to n birds and pig<br>has been associated with low metabolic<br>rate and longevity in pigs and birds.   | Neonatally lethal with onset of<br>abnormalities after mid-gestation<br>leading to traits including<br>complete failure of kidney<br>development.  | Several tissues, particularly kidney.   | 60,169        |
|  | HS6ST1 | No pathogenic variants reported possibly<br>because lethal.<br>SNP association with delayed puberty and<br>idiopathic hypogonadotrophic<br>hypogonadism.   | Lethal at late embryonic stages,<br>with abnormalities in lung<br>morphology, angiogenesis, and<br>retinal axon guidance. If viable,<br>mice showed growth retardation<br>and lung defects.  | Several organs: lung,<br>kidney, cartilage,<br>vascular system,<br>reproduction<br>organs, etc. | 59            |

516 Moreover, no pathogenic variants are known in human for HS2ST1, HS6ST1, or GLCE, possibly 517 because lethal. However, individuals with compound heterozygous NDST1 mutations can survive, although with brain and muscle overt phenotypes<sup>58</sup>. This is possibly due to NDST2 redundance, as 518 519 *NDST2* is not expressed in brain and skeletal muscle (Fig. 4)<sup>58,166</sup>. Together, these data support that 520 uHS sequences synthetized by the Group I HSPG biosynthetic machinery could be those which, 521 depending on their level of expression in each tissue, form HS sequences able to interact and 522 regulate the activities of heparin binding proteins that assure tissue basal functions and homeostasis, 523 as growth factors, morphogens, and other pericellular and cell membrane-associated proteins 524 centrally involved in normal development and homeostasis.

### 525 **3.5.2.** Non-essential HS in the appropriate response to stimuli

526 NDST2, NDST3, NDST4, HS6ST2, HS6ST3, and all HS3STs, are tissue restricted sulfotransferases 527 coded by genes clustered in Group IV (Fig. 4, Fig. 5, and Suppl. Inf). No pathogenic variants are 528 known for any of these genes and the corresponding knockout mice, when available, develops 529 normally, are fertile, and live healthy (Table 4, and Supp. Inf.). Although it cannot be excluded that 530 absence of deleterious phenotypes can be due to compensation phenomena, polymorphisms in 531 most of these genes have been associated with resistance or risk to altered conditions affecting the 532 organs in which they are expressed (Tables 4, see Suppl. Inf.). For instance, in brain, SNP in NDST3 533 has been associated with risk of schizophrenia and bipolar disorders<sup>99,101</sup>, SNP in *NDST4* has been 534 associated with reading difficulty and language impairment<sup>102</sup>, SNP in HS6ST2 has been associated with intellectual disability<sup>105</sup>, SNP in HS6ST3 has been associated with dysregulation of satiety<sup>101,106</sup>. 535 and SNP in HS3ST1 has been associated with to Alzheimer's disease<sup>108,110</sup>. Moreover, the 536 involvement of some of these genes in the appropriate response to neurological stimuli is starting to 537 be documented. For instance, the Ndst37- mouse exhibited subtle impaired anxiety with not 538 compensatory effects from other *Ndst*<sup>100</sup> while HS3ST2 expression was increased in the rat pineal 539 540 gland after adrenergic stimulation<sup>170</sup>, indicating a role of these enzymes in adaptative neurological 541 functions.

542 In peripheral tissues, several polymorphisms have been associated, along or in combination with 543 other genes, with altered conditions or susceptibility to disease (Table 4). For instance in coronary artery diseases (HS3ST1), ulcerative and Crohn's colitis (HS3ST2)<sup>111</sup>, chronic obstructive pulmonary 544 disease (HS3ST2)<sup>112</sup>, and hereditary angioedema (HS3ST6)<sup>119</sup>. The importance of these genes in 545 546 the regulation of response to stimuli is also supported by available knockout mice and biomedical research. For instance, the Hs3st1 null mouse showed a strong proinflammatory phenotype<sup>109</sup>, 547 HS3ST3B1 was shown to be involved in T lymphocytes activation<sup>171</sup>, HS3ST3A1 expression was 548 549 found increased during normotensive and pre-eclamptic pregnancies<sup>113</sup>, and NDST2 was essential for mast cells responsiveness during inflammation and during innate and adaptive immunity toward 550 551 pathogens<sup>172</sup>. Moreover, 3-O-sulfated HS (3S-HS) are well known to increase susceptibility to

- 552 infection by pathogens<sup>12</sup>. Accordingly, polymorphism in both *HS3ST3A1 and HS3STB1* has been
- 553 associated with risk to *P. falciparum* infection<sup>173</sup> and some 3S-HS structures trigger HSV infection<sup>12</sup>.

**Table 4**. **Tissue restricted heparan sulfate (rHS) biosynthetic genes.** Genes are organized based on their

555 expression in human tissues, traits of clinical variants, and/or phenotype of the corresponding null mice.

|  | Gene     | Impact of genetic variants<br>in human  | Phenotype of the null<br>mouse   | Most affected organs or<br>tissues     | Ref.               |
|--|----------|---|--|--|--------------------|
|  | NDST2    | No pathogenic variants reported.<br>SNP association with risk of<br>coronary artery disease and<br>chronic kidney disease.  | Viable, healthy, and fertile.<br>Mast cell shows decreased<br>sulfation in HS.   | Mast cells                             | 176,177            |
|  | HS6ST2   | No pathogenic variants reported.<br>SNP association with risk of X-<br>linked intellectual disability and<br>myopia.  | Viable, healthy, and fertile.  | Brain and cartilage.                   | 105                |
| ssion  | HS6ST3   | No pathogenic variants reported.<br>SNP association with decreased<br>risk to obesity and to increased<br>diabetic retinopathy.   | Not reported.  | Brain, eye.                            | 107,178            |
| GROUP IV<br>Non-essential<br>Partial restricted expression | HS3ST1   | No pathogenic variants reported.<br>SNP association with risk of<br>arteriosclerosis, coronary artery<br>diseases, and Alzheimer's disease.   | Viable, healthy, and fertile but<br>show proinflammatory<br>phenotype when submitted to<br>pathologic stimuli.                                       | Vascular system and brain.             | 179,180            |
| GF<br>Non<br>Partial restr                                 | HS3ST2   | No pathogenic variants reported.<br>Expression is increased in<br>Alzheimer's disease. SNP<br>association with risk of<br>schizophrenia.  | Viable, healthy, and fertile.<br>Responds to adrenergic<br>response to light stimuli.  | Brain.                                 | 12,170,<br>181     |
|  | HS3ST3A1 | No pathogenic variants reported.<br>SNP association with risk of HSV1<br>and <i>P. falciparum</i> infection.  | Not reported.  | Vascular system.                       | 173,182            |
|  | HS3ST3B1 | No pathogenic variants reported.<br>SNP association with risk of <i>P. falciparum</i> infection.  | Not reported. But<br>overexpression affects<br>immunity (peripheral T<br>lymphocytes and Jurkat T cells<br>adaptive response to stimuli).            | Immune system.                         | 173,182<br>183     |
|  | NDST3    | No pathogenic variants reported.<br>SNP association with risk of<br>mental disorders as schizophrenia<br>and bipolar disorders.   | Develop normally, are fertile,<br>and show only subtle<br>hematological and behavioral<br>abnormalities, with reduced<br>anxiety.                    | Brain.                                 | 99-101             |
| ession   | NDST4    | No pathogenic variants reported.<br>SNP association with risk of<br>reading disability and language<br>impairment.  | No pathological outcomes, but<br>some anomalies can be<br>observed in histology images of<br>the proximal colon, where the<br>gene is not expressed. | In cartilage, brain, immune<br>system. | 102,103            |
| GROUP IV<br>Non-essential<br>High restricted express       | HS3ST4   | No pathogenic variants reported.<br>SNP association with risk of<br>altered verbal declarative<br>memory, age-related macular<br>degeneration, schizophrenia, and<br>Alzheimer's disease. | Not reported.  | Brain.                                 | 116,117<br>178,184 |
| High   | HS3ST5   | No pathogenic variants reported.<br>SNP association with risk of<br>intellectual disability and altered<br>gray matter volume in<br>schizophrenia.  | Not reported.  | Brain.                                 | 117,18             |
|  | HS3ST6   | schizophrenia.<br>No pathogenic variants reported.<br>SNP association with risk of<br>altered response to stimuli that<br>triggers angioedema.  | Not reported.  | Skin, vascular system.                 | 118,11             |

### 557 **3.5.3. HS chain remodeling and biosynthesis arrest**

558 After biosynthesis, HSPG are secreted to the cell surface or to the pericellular space, where their HS chains can be remodeled by SULF1, SULF2<sup>14</sup>, and/or by heparanase<sup>15</sup>, which activity can be 559 negatively regulated by the enzymatically inactive heparanase 2<sup>67</sup> (Table 5). Although no clinical 560 variants are known for SULF2, the Sulf2<sup>-/-</sup> mouse shows lethality<sup>14</sup> (included in Group I), whereas in 561 562 human, HPSE2 variants result in pos-developmental syndromes (included in Group II), and other altered conditions (Suppl. Inf.)<sup>68,174,175</sup>. This indicates that both SULF2 and HPSE2 are required for 563 normal homeostasis and basal response to stimuli. The involvement of HPSE2 in response to stimuli 564 565 was confirmed in the homozygous Hpse2 gene trap mouse, which developed normally but showed 566 deficient responses to chemical and electrical field stimulation and showed low weight gain after weaning and died early in life<sup>174,175</sup>. In the other side, both Sulf1<sup>-/-</sup> and hpse<sup>-/-</sup> mice develop and live 567 normally, are anatomically normal fertile, and show non overt phenotypes<sup>14,186</sup> (included in Group 568 569 III). Accordingly, non-pathogenic variants are known in human(Table 5). However, SNP has been 570 associated with chronic graft-versus-host disease<sup>84</sup>, supporting its clustering in Group III. 571 Accordingly, as for other genes in Group III, nonpathogenic SULF1 variants are known, but 572 polymorphism has been associated to multiple sclerosis<sup>70</sup>, fetus failure during *in vitro* fertilisation<sup>88</sup>, 573 and preeclampsia<sup>89</sup> (Table 5).

574 **Table 5. Genes coding for heparan sulfates remodeling enzymes.** Genes are organized based on their 575 expression in human tissues, clinical variants traits, and/or phenotype of the corresponding null mice.

|   | Gene  | Impact of genetic variants<br>in human   | Phenotype of the null<br>mouse   | Most affected organs or<br>tissues                               | Ref             |
|---|-------|--|--|--|-----------------|
| GROUP I<br>Essential<br>Widely<br>expressed           | SULF2 | No pathogenic variants reported.<br>SNP associations with risk to<br>altered regulation of lipoprotein<br>metabolism, fasting, and<br>postprandial triglycerides<br>clearance. | Significant lethality with<br>reduction in brain mass during<br>neuronal development with<br>some kidney, lung, and skeletal<br>defects. | Various, including brain, kidney,<br>lung, skeletal tissue, etc. | 168,187-<br>189 |
| GROUP II<br>Essential<br>restricted<br>expression     | HPSE2 | No pathogenic variants reported.<br>SNP high associating with<br>urofacial syndrome and that<br>separates migraine with and<br>without depression.                             | Viable, anatomically normal, and fertile.  | Urinary system, facial tissue,<br>brain.                         | 68,174,<br>175  |
| al<br>sed   | EXTL2 | No pathogenic variants reported.   | Normal embryonic<br>development. Healthy during<br>adult life but show altered<br>recovery after tissue injury.                          |  | 82,83           |
| GROUP III<br>Non-essential<br>Widely expressed        | SULF1 | No pathogenic variants reported.<br>SNP association with multiple<br>sclerosis, fetus failure in IVF<br>technique, and preeclampsia.   | Non-overt phenotype, viable<br>with no phenotypic or<br>histological defects.  |  | 70,88,<br>89    |
| Wic   | HPSE  | No pathogenic variants reported.<br>SNP association with chronic<br>graft-versus-host disease.   | Viable, anatomically normal, and fertile.  |  | 84,86,<br>186   |
| GROUP IV<br>Non-essential<br>restricted<br>expression | EXTL1 | No pathogenic variants reported.<br>SNP association with muscle lipid<br>composition, although without<br>pathologic impact.   | Primary cultures of B-cells from<br>mouse overexpressing Extl1<br>showed altered maturation<br>capacities.                               |  | 120,190         |

576 Moreover, although widely distributed, *HPSE* and SULF1 basal expressions are low (Fig. 4), possibly 577 because it is mainly required during tissue remodeling, as during wound healing, inflammation, and 578 tumor growth and metastasis<sup>15</sup>. Interestingly, this is also the case for HPSE2 (Fig. 4), which main 579 action could also be regulatory during endogenous stimuli. Together, these reports suggest that 580 arrest of HS biosynthesis and HS chain remodeling predominantly occurs when cells and tissues are 581 submitted to instigating or adaptative conditions, and that their SNP might predispose disease.

### 582 **3.5.4.** Stimuli driven arrest of HS chain initiation or elongation

583 During biosynthesis, EXTL1 (Group IV) and EXTL2 (Group III) can control HS levels by respectively 584 blocking chain elongation or chain initiation when the biosynthetic machinery is overactivated, for 585 instance during wound healing, during adaptative immunological response of cells, or following other 586 internal or external stimuli<sup>13</sup>. No pathogenic variants have been reported for neither of these genes 587 and no genetic polymorphism has been associated with disease (Table 5). Indeed, to date, only 588 polymorphism in EXTL1 has been associated with muscle lipid composition, although without 589 pathologic impact<sup>120</sup>. However, in vitro, primary cultures of B-cells from mouse overexpressing Ext/1 590 showed altered maturation capacities<sup>190</sup> (Table 5), suggesting that but the enzyme might be involved 591 in generation of environments or processed assuring an appropriate responsiveness to stimuli, including immunological stimuli<sup>190</sup>. Similarly, the *Extl2<sup>-/-</sup>* mouse showed non overt phenotype, 592 although presented impaired recovery following liver and kidney injury<sup>82,83</sup>. These data suggest that 593 594 arrest of HS chain initiation or elongation is not essential during development and homeostasis but 595 is required for appropriate response to stimuli and that SNP can predispose to altered conditions 596 with or without clinical significance.

## 597 **4.** Discussion

598 HSPGs are among the more complex molecules in biology due to their HS structural and functional 599 diversity. This diversity results from the complexity of their biosynthetic machinery coded by dozens 600 of genes, which unclear relation to each other has hidden advances in the understanding of 601 proteoglycans biology. Here, by following the PRISMA guidelines for systematic reviews and meta-602 analysis<sup>18</sup>, we retrieved information for the 50 main human HSPG biosynthetic genes, including 603 those shared with the CSPG biosynthesis through the GAG-CP-linker tetrasaccharide, and for other 604 genes involved in Golgian homeostasis. Analysis of the documented relationship between human 605 pathogenic variants, SNPs associations with altered conditions or susceptibility to disease, null mice 606 phenotypes, gene expression profiles, and substrates specificities of enzymes coded by the 607 biosynthetic genes, resulted in the clustering in 4 Groups of genes organized depending on their 608 essentialness and expression (Fig. 5). Globally, Group I integrates ubiquitous genes which by themselves can produce complete HSPG, as the group included genes coding for cores protein, all the GAG-CP linker biosynthetic enzymes, and glycosyltransferases and three sulfotransferases involved in the synthesis of a complete HS chain. Concerning the core proteins, Group I included genes coding for all the full time pericellular HSPG core proteins (perlecan, agrin, and collagen 18)<sup>1</sup> and for 3 membrane-associated glypicans (glypicans 3, 4, and 6)<sup>125</sup>, indicating that this group can afford both essential pericellular HSPG involved structure and function of the pericellular matrix and and cell membrane-associated HSPG involved in cell signaling.

616 Concerning the GAG-CP linker tetrasaccharide coding genes, analysis of their clinical variants, null 617 mice phenotypes, and substrate selectivities of their coded enzymes, resulted in a new organization 618 of the GSG-CP linker biosynthetic pathway in which the HSPG synthesis is primarily assured over 619 that of CSPG and in which the phenotypic continuum of disorders as linkeropathies and other pathologies is understandable<sup>52,140,191</sup>. Moreover, this new representation of the GAG-CP linker 620 621 biosynthetic genes supports the idea that HSPG biosynthetic enzymes can assemble into 622 'GAGosmes'<sup>64,192</sup>, or 'Proteoglycanomes'<sup>193</sup>, which consider the integration of proteoglycan core 623 proteins in the protein complexes that assure proteoglycans synthesis in the Golgi. Indeed, common 624 protein modules in the ubiquitous/essential pericellular perlecan and agrin (Group I) are different 625 from those shared by the ubiquitous/non-essential syndecans (Group III)<sup>1</sup>, but common to those in 626 CSPGs aggrecan and neurocan, suggesting that agrin, perlecan, aggrecan, and neurocan can 627 circulate through a common HSPG/CSPG path during GAG-CP linker synthesis, as proposed in Fig. 628 6A. Moreover, aggrecan and neurocan modules are different from those carried by decorin<sup>1</sup>, 629 supporting the splitting of the CSPG-decorin path from the HSPG/CSPG-aggrecan path under 630 interaction with XYLT1 at early steps of the GAG-CP linker biosynthesis (Fig. 6A). Likewise, 631 syndecans modules are different from those carried by agrin, perlecan, aggrecan, neurocan, and 632 decorin<sup>1</sup>, suggesting that the tissue restricted syndecans might integrate protein complexes different 633 to those in which the ubiquitous core proteins are integrated. Thus, it will be important to investigate 634 whether the tissue restricted HS biosynthetic enzymes in Groups III and IV contain protein modules 635 that could associate them to syndecans or to other tissue restricted core proteins. Answering to this 636 question will give information on whether rHS can be carried by uCP (Fig. 6C), as syndecans, but 637 not only.

Concerning the HS chain, the EXTL3, EXT1, and EXT2 glycosyltransferases coding genes 638 639 comprehensibly clustered in Group I, which contains genes that are essential for normal 640 development and homeostasis (EXTL3, EXT1, and EXT2 are required for constructing the HSPG 641 polysaccharide). Moreover, Group I clustered the ubiquitous NDST1, GLCE, HS2ST1, and HS6ST1, 642 which appeared to be involved in the generation of uHS sequences that can then be those essential 643 for normal development and homeostasis. In the other side, the tissue restricted NDST2-4, HS6ST2-644 3, and HS3ST1-6 appeared to generate specialized rHS sequences mainly involved in 645 responsiveness to stimuli. Based in their substrate specificities<sup>59,159-163</sup>, NDST1 and HS6ST1, in 646 association with HS2ST and GLCE, likely form uHS NA/NS domains (Supp. Inf.), which sulfation 647 level in each position might vary depending on these ubiquitous gene expression levels in the different tissues or cells<sup>63-65</sup>. Indeed, NDST1 generates HS domains with lower level of *N*-sulfation 648 than NDST2<sup>164</sup> while HS6ST1 shows higher selectivity for non-2-O-sulfated residues (hexA-GlcNS), 649 650 as confirmed in the Hs6st1 null mouse<sup>59</sup>. In the other side, mostly based in the presence of 3-O-651 sulfation and higher levels of N- and 6-O-sulfations that result from NDST2 and HS6ST2 substrate specificities<sup>12,97,100,159,161-163,177,194-199</sup>, it appeared that specialized rHS are formed by NS 652 domains<sup>12,162,177</sup>. The existence of different synthetic paths leading to NA/NS or NS domains agrees 653 654 the HS biosynthetic tree proposed by Yates el al. in which different enzymes specificities and 655 substrate abundances can determine the HS synthesis direction either through a major branch 656 assuring commonly occurring HS disaccharides or a minor branch assuring least common disaccharides<sup>200</sup>. Separation of the two branches seems to be associated to the relative abundance 657 658 of two sets of structures resulting from the C5-epimerase preference to convert GIcA-GIcNS to IdoA-GlcNS compared to converting GlcA-GlcNAc to IdoA-GlcNAc<sup>65,200</sup>. Thus, because they are made by 659 essential biosynthetic machinery, uHS NA/NS sequences might be those that are essential for 660 661 normal development and homeostasis, whereas the specialized rHS sequences generated by 662 enzymes coded by Group IV genes (NDST2, NDST3, NDST4, HS6ST2, HS6ST3, and all HS3STs) might be involved in specific biological functions. Accordingly, they are required for assuring 663 664 adaptative behaviors and/or for proper responsiveness to instigating stimuli in the tissues or cells in 665 which they are expressed.

666

#### 667 Ideas and Speculation

668 This work highlighted the possible existence of uHS likely tailored by NDST1, HS6ST1 in associating 669 with HS2ST and GLCE, which together can form NA/NS domains. However, experimental evidence 670 directly demonstrating that uHS sequences in ubiquitous HSPG are formed of NA/NS require to be 671 established. Nevertheless, because of their essentialness, one can speculate that these uHS 672 sequences are those that interact and regulate HBP required for normal development and 673 homeostasis, including matrix proteins (collagen, laminin, etc.), growth factors (FGFs, VEGF, PDGF, 674 BDNF, GDNF, etc.), morphogens (Wint, hedgehog, etc.), lipid binding proteins (apolipoproteins, lipoprotein lipase, etc.), cell adhesion proteins (P and L-selectin, integrins, etc.), among others<sup>17,165</sup>. 675 676 Interestingly, several of these factors have been involved in cancer development and growth. Indeed, 677 if NA/NS sequences are those that under physiological conditions interact with these factors and 678 potentiated their activities, their excess might have over-signaling related oncogenic effects. 679 Interestingly, SULF2 is a 6-O-sulfatase that shows strong pro-oncogenic activity and that also 680 clustered in Group I. Thus, by de-sulfating NS sequences, SULF2 can generate biologically active 681 NA/NS-like sequences that potentiate growth factors activities. If this is the case SULF2 will be pro-682 oncogenic, as is the case<sup>14</sup>. Although compensation phenomena among SULF1 and SULF2 can be 683 argued, it noteworthy that while SULF2 is a pro-oncogene, SULF1 shows anti-oncogenic activity<sup>14</sup>, 684 suggesting differential functions. Accordingly, SULF1 might inactivate excess of NA/NS sequences by de-sulfating uHS and thus generating under-sulfated 6-O-desulfated NA/NS domains unable to 685 promote HBP trophic effects<sup>14,62</sup>. Thus, it is possible that by generating biologically active NA/NS-686 like sequences, SULF2 favors growth factors activities acting as pro-oncogene, whereas SULF1 687 688 participate to inactivation of active NA/NS sequences by generating under sulfated and inactive 689 NA/NS domains, acting as anti-oncogene. This hypothesis requires large research to be confirmed 690 or discarded. Similarly, based in information from the knockout mice and GWAS data, it appeared 691 that specialized rHS sequences are those required for appropriate responsiveness to stimuli and 692 adaptive behaviors in tissues in which each gene is specifically expressed. An additional question of 693 interest is whether these specialized rHS are those that afford to HS chains their fine structural 694 specificity, which will then not be directly related to fundamental processes in life, but mostly to 695 specific tissue responsiveness to stimuli, resistance or vulnerability to disease or altered behaviors, 696 as those observed in complex neurological disorders. Moreover, it is possible that rHS sequences 697 (their biosynthetic genes knockout mice lives healthy) are carried by Group II and III core proteins 698 (their biosynthetic genes knockout mice lives healthy), whereas uHS sequences (their biosynthetic 699 genes knockout mice die) are carried by the ubiquitous core proteins (their biosynthetic genes 700 knockout mice die). Answering to these questions will facilitate research aiming to understand the 701 differential role of HSPG core proteins and the HS chains that they carry in a large variety of 702 biological and pathological context. Thus, although to date it is not yet possible to sequence single 703 HS chains isolated from their physiological contexts, the selective purification of core proteins from 704 tissues or cells will make available their specific HS chains, in which the research of NA/NS or NS 705 sequences could be performed. Finally, as HS chains are long, one should consider that the 706 specialized rHS sequences might be those that gives to cells the capacity to generate specific HS 707 interactomes with cell membrane proteins, or matrix proteins. The involvement of Group IV rHS 708 biosynthetic genes in complex pathologies, as neurologic or behavioral disorders, might represent a 709 solution for the identification of pathologies associating specific rHS interactomes. We are currently 710 working in this direction.

711 In conclusion, by analyzing clinical variants and transcriptomic databases and literature records for 712 biochemical and functional information on HSPG biosynthetic machinery genes, we decrypted 713 essential features of proteoglycans and HS structural and functional diversity. Our analysis considers 714 new concepts non developed in previous works, for instance those in which HS structures are defined by the HSPG biosynthetic genes expression levels<sup>63-65</sup>. From this analysis, we propose a 715 716 clinical-variant and substrate selectivity-based proteoglycan biosynthetic pathway in which HSPG 717 are primarily assured over CSPG, and in which the HS chains or sequences are characterized for 718 carrying either an ubiquitous 'sulfation level specificity' (uHS) or a specialized 'sulfation pattern

specificity' (rHS), depending on the tissue in where they are made. This work opens new routes of
 research for a better understanding of the roles of HSPG in physiology and pathology.

## 721 5. Acknowledgments

722 This work has received funding from the ANR SkelGAG and from the European Union's Horizon 723 2020 Research and Innovation Program (grant agreement No 737390). G. Barreto was funded by 724 the "Centre National de la Recherche Scientifique" (CNRS, France), "Délégation Centre-Est" (CNRS-725 DR6), the "Lorraine Université" (LU, France) through the initiative "Lorraine Université d'Excellence" 726 and the dispositive "Future Leader" and the "Deutsche Forschungsgemeinschaft" (DFG, Bonn, 727 Germany) (BA 4036/4-1). We thank ArrestAD partners, particularly Prof. T. van Kuppevelt (Radboud 728 University, the Netherlands) and Prof. D. Fernig (University of Liverpool, UK), to Prof. P. Albanese, 729 Dr. A. Fifre (University Paris Est Créteil, France), Prof. J-P. Li, Prof. U. Lindahl, and Prof. L. Kjellen 730 (Uppsala University, Sweden), for interesting discussions.

## 731 6. Competing interests

The authors declare that they have no competing interests.

## 733 **7.** Author contributions

DPG designed the study and wrote the manuscript. DPG, MOO, BDSF, and JDR analyzed the data. DPG, GB, BDSF, and MMO participated to data organization. DPG, MOO, GB, NR, and AM participated to figures design. SC, MBH, XL, GLD, and OGV participated to data analysis and literature review. All authors discussed results and commented the manuscript for improvement.

## 738 **References**

- 7391Iozzo, R. V. & Schaefer, L. Proteoglycan form and function: A comprehensive nomenclature of<br/>proteoglycans. *Matrix Biol* 42, 11-55, doi:10.1016/j.matbio.2015.02.003 (2015).
- 7412Li, J. P. & Kusche-Gullberg, M. Heparan Sulfate: Biosynthesis, Structure, and Function. International742review of cell and molecular biology **325**, 215-273, doi:10.1016/bs.ircmb.2016.02.009 (2016).
- 7433Sarrazin, S., Lamanna, W. C. & Esko, J. D. Heparan sulfate proteoglycans. Cold Spring Harbor744perspectives in biology 3, doi:10.1101/cshperspect.a004952 (2011).
- 7454Gao, J. & Huang, X. Recent advances on glycosyltransferases involved in the biosynthesis of the<br/>proteoglycan linkage region. Advances in carbohydrate chemistry and biochemistry 80, 95-119,<br/>doi:10.1016/bs.accb.2021.10.003 (2021).
- 7485Sasarman, F. et al. Biosynthesis of glycosaminoglycans: associated disorders and biochemical tests.749Journal of inherited metabolic disease **39**, 173-188, doi:10.1007/s10545-015-9903-z (2016).

- 7506Wen, J. et al. Xylose phosphorylation functions as a molecular switch to regulate proteoglycan751biosynthesis. Proceedings of the National Academy of Sciences of the United States of America 111,75215723-15728, doi:10.1073/pnas.1417993111 (2014).
- 753 7 Koike, T., Izumikawa, T., Sato, B. & Kitagawa, H. Identification of phosphatase that dephosphorylates
   754 xylose in the glycosaminoglycan-protein linkage region of proteoglycans. *The Journal of biological* 755 *chemistry* 289, 6695-6708, doi:10.1074/jbc.M113.520536 (2014).
- 7568Paganini, C. et al. Calcium activated nucleotidase 1 (CANT1) is critical for glycosaminoglycan757biosynthesis in cartilage and endochondral ossification. Matrix Biol 81, 70-90,758doi:10.1016/j.matbio.2018.11.002 (2019).
- 7599Paganini, C., Gramegna Tota, C., Superti-Furga, A. & Rossi, A. Skeletal Dysplasias Caused by760Sulfation Defects. International journal of molecular sciences **21**, doi:10.3390/ijms21082710 (2020).
- 76110Dubail, J. et al. SLC10A7 mutations cause a skeletal dysplasia with amelogenesis imperfecta762mediated by GAG biosynthesis defects. Nature communications 9, 3087, doi:10.1038/s41467-018-76305191-8 (2018).
- Li, J. P. Glucuronyl C5-epimerase an enzyme converting glucuronic acid to iduronic acid in heparan sulfate/heparin biosynthesis. *Progress in molecular biology and translational science* 93, 59-78, doi:10.1016/s1877-1173(10)93004-4 (2010).
- 76712Thacker, B. E., Xu, D., Lawrence, R. & Esko, J. D. Heparan sulfate 3-O-sulfation: a rare modification768in search of a function. *Matrix Biol* **35**, 60-72, doi:10.1016/j.matbio.2013.12.001 (2014).
- 76913Busse-Wicher, M., Wicher, K. B. & Kusche-Gullberg, M. The exostosin family: proteins with many770functions. *Matrix Biol* **35**, 25-33, doi:10.1016/j.matbio.2013.10.001 (2014).
- 77114El Masri, R., Seffouh, A., Lortat-Jacob, H. & Vives, R. R. The "in and out" of glucosamine 6-O-sulfation:772the 6th sense of heparan sulfate. Glycoconjugate journal 34, 285-298, doi:10.1007/s10719-016-9736-7735 (2017).
- 77415Masola, V., Bellin, G., Gambaro, G. & Onisto, M. Heparanase: A Multitasking Protein Involved in775Extracellular Matrix (ECM) Remodeling and Intracellular Events. Cells 7, doi:10.3390/cells7120236776(2018).
- 77716Mayfosh, A. J., Nguyen, T. K. & Hulett, M. D. The Heparanase Regulatory Network in Health and<br/>Disease. International journal of molecular sciences 22, doi:10.3390/ijms222011096 (2021).
- 77917Xie, M. & Li, J. P. Heparan sulfate proteoglycan A common receptor for diverse cytokines. Cell Signal78054, 115-121, doi:10.1016/j.cellsig.2018.11.022 (2019).
- 78118Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.782Rev Esp Cardiol (Engl Ed) 74, 790-799, doi:10.1016/j.rec.2021.07.010 (2021).
- 78319Papatheodorou, I. *et al.* Expression Atlas: gene and protein expression across multiple studies and<br/>organisms. *Nucleic Acids Res* 46, D246-D251, doi:10.1093/nar/gkx1158 (2018).
- 78520Filippi, L. & Braat, A. J. Theragnostics in primary and secondary liver tumors: the need for a786personalized approach. The quarterly journal of nuclear medicine and molecular imaging : official787publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of788Radiopharmacology (IAR), [and] Section of the So 65, 353-370, doi:10.23736/s1824-4785.21.03407-7895 (2021).
- Marques, C., Reis, C. A., Vivès, R. R. & Magalhães, A. Heparan Sulfate Biosynthesis and Sulfation
   Profiles as Modulators of Cancer Signalling and Progression. *Frontiers in oncology* 11, 778752, doi:10.3389/fonc.2021.778752 (2021).
- 79322Arikawa-Hirasawa, E., Watanabe, H., Takami, H., Hassell, J. R. & Yamada, Y. Perlecan is essential794for cartilage and cephalic development. *Nature genetics* 23, 354-358, doi:10.1038/15537 (1999).
- 79523Gubbiotti, M. A., Neill, T. & Iozzo, R. V. A current view of perlecan in physiology and pathology: A796mosaic of functions. *Matrix Biol* **57-58**, 285-298, doi:10.1016/j.matbio.2016.09.003 (2017).
- Liu, H. & Huang, W. The Association between Genes Polymorphisms of Heparan Sulfate Proteoglycan
  2 (HSPG2) and Chondroitin Sulfate Proteoglycan 2 (CSPG2) and Intracranial Aneurysm Susceptibility:
  A Meta-Analysis. *Iranian journal of public health* 48, 1945-1951 (2019).
- 80025Martinez, J. R., Dhawan, A. & Farach-Carson, M. C. Modular Proteoglycan Perlecan/HSPG2:801Mutations, Phenotypes, and Functions. *Genes* 9, doi:10.3390/genes9110556 (2018).
- 80226Daniels, M. P. The role of agrin in synaptic development, plasticity and signaling in the central nervous803system. Neurochemistry international 61, 848-853, doi:10.1016/j.neuint.2012.02.028 (2012).
- 804 27 Gautam, M. *et al.* Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. *Cell* **85**, 525-535, doi:10.1016/s0092-8674(00)81253-2 (1996).

- 80628Hausser, H. J., Ruegg, M. A., Brenner, R. E. & Ksiazek, I. Agrin is highly expressed by chondrocytes807and is required for normal growth. *Histochemistry and cell biology* **127**, 363-374, doi:10.1007/s00418-808006-0258-2 (2007).
- 80929Nicole, S. *et al.* Agrin mutations lead to a congenital myasthenic syndrome with distal muscle810weakness and atrophy. *Brain : a journal of neurology* **137**, 2429-2443, doi:10.1093/brain/awu160811(2014).
- 812 30 Fukai, N. *et al.* Lack of collagen XVIII/endostatin results in eye abnormalities. *The EMBO journal* 21, 1535-1544, doi:10.1093/emboj/21.7.1535 (2002).
- 814 31 Heljasvaara, R., Aikio, M., Ruotsalainen, H. & Pihlajaniemi, T. Collagen XVIII in tissue homeostasis
  815 and dysregulation Lessons learned from model organisms and human patients. *Matrix Biol* 57-58, 55-75, doi:10.1016/j.matbio.2016.10.002 (2017).
- 81732Seppinen, L. & Pihlajaniemi, T. The multiple functions of collagen XVIII in development and disease.818Matrix Biol **30**, 83-92, doi:10.1016/j.matbio.2010.11.001 (2011).
- 819 33 Cano-Gauci, D. F. *et al.* Glypican-3-deficient mice exhibit developmental overgrowth and some of the
   abnormalities typical of Simpson-Golabi-Behmel syndrome. *The Journal of cell biology* 146, 255-264,
   821 doi:10.1083/jcb.146.1.255 (1999).
- 822 34 Cottereau, E. *et al.* Phenotypic spectrum of Simpson-Golabi-Behmel syndrome in a series of 42 cases
  823 with a mutation in GPC3 and review of the literature. *American journal of medical genetics. Part C,*824 Seminars in medical genetics 163c, 92-105, doi:10.1002/ajmg.c.31360 (2013).
- 825 35 Iglesias, B. V. *et al.* Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. *Histology and histopathology* 23, 1333-1340, doi:10.14670/hh-23.1333 (2008).
- 82736Amor, D. J. et al. Pathogenic Variants in GPC4 Cause Keipert Syndrome. American journal of human<br/>genetics 104, 914-924, doi:10.1016/j.ajhg.2019.02.026 (2019).
- B29 37 Dowling, C. & Allen, N. J. Mice Lacking Glypican 4 Display Juvenile Hyperactivity and Adult Social Interaction Deficits. *Brain plasticity (Amsterdam, Netherlands)* 4, 197-209, doi:10.3233/bpl-180079 (2018).
- 832 38 Campos-Xavier, A. B. *et al.* Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair
  833 endochondral ossification and cause recessive omodysplasia. *American journal of human genetics*834 84, 760-770, doi:10.1016/j.ajhg.2009.05.002 (2009).
- 835 39 Capurro, M. *et al.* Glypican-6 promotes the growth of developing long bones by stimulating Hedgehog
   836 signaling. *The Journal of cell biology* **216**, 2911-2926, doi:10.1083/jcb.201605119 (2017).
- Kemp, J. P. *et al.* Identification of 153 new loci associated with heel bone mineral density and functional
  involvement of GPC6 in osteoporosis. *Nature genetics* 49, 1468-1475, doi:10.1038/ng.3949 (2017).
- 839 41 Bui, C. *et al.* XYLT1 mutations in Desbuquois dysplasia type 2. *American journal of human genetics* 94, 405-414, doi:10.1016/j.ajhg.2014.01.020 (2014).
- 84142Mis, E. K. et al. Forward genetics defines Xylt1 as a key, conserved regulator of early chondrocyte842maturation and skeletal length. Developmental biology 385, 67-82, doi:10.1016/j.ydbio.2013.10.014843(2014).
- Taylan, F. *et al.* Spondyloocular Syndrome: Novel Mutations in XYLT2 Gene and Expansion of the
  Phenotypic Spectrum. *Journal of bone and mineral research : the official journal of the American*Society for Bone and Mineral Research **31**, 1577-1585, doi:10.1002/jbmr.2834 (2016).
- 84744Caraffi, S. G. et al. Severe Peripheral Joint Laxity is a Distinctive Clinical Feature of848Spondylodysplastic-Ehlers-Danlos Syndrome (EDS)-B4GALT7 and Spondylodysplastic-EDS-849B3GALT6. Genes 10, doi:10.3390/genes10100799 (2019).
- 85045Mihalic Mosher, T. et al. Expansion of B4GALT7 linkeropathy phenotype to include perinatal lethal851skeletal dysplasia. European journal of human genetics : EJHG, doi:10.1038/s41431-019-0464-8852(2019).
- Malfait, F. *et al.* Defective initiation of glycosaminoglycan synthesis due to B3GALT6 mutations causes
  a pleiotropic Ehlers-Danlos-syndrome-like connective tissue disorder. *American journal of human genetics* 92, 935-945, doi:10.1016/j.ajhg.2013.04.016 (2013).
- Van Damme, T. *et al.* Biallelic B3GALT6 mutations cause spondylodysplastic Ehlers-Danlos syndrome. *Human molecular genetics* 27, 3475-3487, doi:10.1093/hmg/ddy234 (2018).
- 85848Ritelli, M. *et al.* Further Defining the Phenotypic Spectrum of B3GAT3 Mutations and Literature Review859on Linkeropathy Syndromes. *Genes* **10**, doi:10.3390/genes10090631 (2019).

- Kuroda, Y. *et al.* A novel gene (FAM20B encoding glycosaminoglycan xylosylkinase) for neonatal short
  limb dysplasia resembling Desbuquois dysplasia. *Clinical genetics* **95**, 713-717,
  doi:10.1111/cge.13530 (2019).
- Spyroglou, A. *et al.* Diastrophic dysplasia sulfate transporter (SLC26A2) is expressed in the adrenal cortex and regulates aldosterone secretion. *Hypertension (Dallas, Tex. : 1979)* 63, 1102-1109, doi:10.1161/hypertensionaha.113.02504 (2014).
- 86651Asselta, R. et al. X Chromosome Contribution to the Genetic Architecture of Primary Biliary867Cholangitis. Gastroenterology 160, 2483-2495.e2426, doi:10.1053/j.gastro.2021.02.061 (2021).
- 86852Taylan, F. & Mäkitie, O. Abnormal Proteoglycan Synthesis Due to Gene Defects Causes Skeletal869Diseases with Overlapping Phenotypes. Hormone and metabolic research = Hormon- und870Stoffwechselforschung = Hormones et metabolisme 48, 745-754, doi:10.1055/s-0042-118706 (2016).
- S3 Osman, N. M., Kagohashi, Y., Udagawa, J. & Otani, H. Alpha1,4-N-acetylglucosaminyltransferase
  encoding gene EXTL3 expression pattern in mouse adult and developing tissues with special attention
  to the pancreas. *Anatomy and embryology* 207, 333-341, doi:10.1007/s00429-003-0348-z (2003).
- 87454Yamada, S. Specific functions of Exostosin-like 3 (EXTL3) gene products. Cellular & molecular biology875letters 25, 39, doi:10.1186/s11658-020-00231-y (2020).
- 55 Lin, X. *et al.* Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice.
   B77 Developmental biology **224**, 299-311, doi:10.1006/dbio.2000.9798 (2000).
- Stickens, D., Zak, B. M., Rougier, N., Esko, J. D. & Werb, Z. Mice deficient in Ext2 lack heparan sulfate
  and develop exostoses. *Development (Cambridge, England)* 132, 5055-5068, doi:10.1242/dev.02088
  (2005).
- Li, J. P. *et al.* Targeted disruption of a murine glucuronyl C5-epimerase gene results in heparan sulfate
   lacking L-iduronic acid and in neonatal lethality. *The Journal of biological chemistry* 278, 28363-28366,
   doi:10.1074/jbc.C300219200 (2003).
- 88458Armstrong, L. *et al.* A girl with developmental delay, ataxia, cranial nerve palsies, severe respiratory885problems in infancy-Expanding NDST1 syndrome. American journal of medical genetics. Part A 173,886712-715, doi:10.1002/ajmg.a.37621 (2017).
- Habuchi, H. *et al.* Mice deficient in heparan sulfate 6-O-sulfotransferase-1 exhibit defective heparan sulfate biosynthesis, abnormal placentation, and late embryonic lethality. *The Journal of biological chemistry* 282, 15578-15588, doi:10.1074/jbc.M607434200 (2007).
- 89060Merry, C. L. *et al.* The molecular phenotype of heparan sulfate in the Hs2st-/- mutant mouse. The<br/>Journal of biological chemistry **276**, 35429-35434, doi:10.1074/jbc.M100379200 (2001).
- 89261Ringvall, M. & Kjellen, L. Mice deficient in heparan sulfate N-deacetylase/N-sulfotransferase 1.893Progress in molecular biology and translational science 93, 35-58, doi:10.1016/s1877-1173(10)93003-8942 (2010).
- Chiu, L. T. *et al.* Trisaccharide Sulfate and Its Sulfonamide as an Effective Substrate and Inhibitor of Human Endo-O-sulfatase-1. *Journal of the American Chemical Society* 142, 5282-5292, doi:10.1021/jacs.0c00005 (2020).
- Lindahl, U. & Kjellen, L. Pathophysiology of heparan sulphate: many diseases, few drugs. *J Intern Med* 273, 555-571, doi:10.1111/joim.12061 (2013).
- 90064Kreuger, J. & Kjellén, L. Heparan sulfate biosynthesis: regulation and variability. The journal of<br/>histochemistry and cytochemistry : official journal of the Histochemistry Society 60, 898-907,<br/>doi:10.1369/0022155412464972 (2012).
- 90365Huang, Y. F., Mizumoto, S. & Fujita, M. Novel Insight Into Glycosaminoglycan Biosynthesis Based on904Gene Expression Profiles. Frontiers in cell and developmental biology 9, 709018,905doi:10.3389/fcell.2021.709018 (2021).
- 90666Grobe, K. & Esko, J. D. Regulated translation of heparan sulfate N-acetylglucosamine N-<br/>deacetylase/n-sulfotransferase isozymes by structured 5'-untranslated regions and internal ribosome<br/>entry sites. The Journal of biological chemistry 277, 30699-30706 (2002).
- 90967Pinhal, M. A. S., Melo, C. M. & Nader, H. B. The Good and Bad Sides of Heparanase-1 and<br/>Heparanase-2. Advances in experimental medicine and biology 1221, 821-845, doi:10.1007/978-3-<br/>030-34521-1\_36 (2020).
- 912 68 Petschner, P. *et al.* A replication study separates polymorphisms behind migraine with and without depression. *PloS one* **16**, e0261477, doi:10.1371/journal.pone.0261477 (2021).
- 91469Nemoto, T. et al. Endothelial glycocalyx and severity and vulnerability of coronary plaque in patients915with coronary artery disease. Atherosclerosis **302**, 1-7, doi:10.1016/j.atherosclerosis.2020.04.014916(2020).

- 91770Okolicsanyi, R. K., Bluhm, J., Miller, C., Griffiths, L. R. & Haupt, L. M. An investigation of genetic918polymorphisms in heparan sulfate proteoglycan core proteins and key modification enzymes in an919Australian Caucasian multiple sclerosis population. Human genomics 14, 18, doi:10.1186/s40246-920020-00264-6 (2020).
- 92171Saboia, Z., Meneses, G. C., Martins, A. M. C., Daher, E. F. & Silva Junior, G. B. Association between922syndecan-1 and renal function in adolescents with excess weight: evidence of subclinical kidney923disease and endothelial dysfunction. Brazilian journal of medical and biological research = Revista924brasileira de pesquisas medicas e biologicas 51, e7174, doi:10.1590/1414-431x20177174 (2018).
- 92572Ashley-Koch, A. E. *et al.* Genome-wide association study of posttraumatic stress disorder in a cohort926of Iraq-Afghanistan era veterans. Journal of affective disorders184, 225-234,927doi:10.1016/j.jad.2015.03.049 (2015).
- 92873Chang, B. C., Hwang, L. C. & Huang, W. H. Positive Association of Metabolic Syndrome with a Single929929Nucleotide Polymorphism of Syndecan-3 (rs2282440) in the Taiwanese Population. International930journal of endocrinology **2018**, 9282598, doi:10.1155/2018/9282598 (2018).
- Ha, E. *et al.* Positive association of obesity with single nucleotide polymorphisms of syndecan 3 in the
  Korean population. *The Journal of clinical endocrinology and metabolism* **91**, 5095-5099,
  doi:10.1210/jc.2005-2086 (2006).
- 93475Moons, T. *et al.* Clock genes and body composition in patients with schizophrenia under treatment935with antipsychotic drugs. Schizophrenia research 125, 187-193, doi:10.1016/j.schres.2010.10.008936(2011).
- 93776Schüring, A. N. et al. Role of syndecan-3 polymorphisms in obesity and female hyperandrogenism.938Journal of molecular medicine (Berlin, Germany) 87, 1241-1250, doi:10.1007/s00109-009-0529-1939(2009).
- 94077De Luca, M. *et al.* A conserved role for syndecan family members in the regulation of whole-body941energy metabolism. *PloS one* **5**, e11286, doi:10.1371/journal.pone.0011286 (2010).
- 94278Nagy, N. et al. The altered expression of syndecan 4 in the uninvolved skin of venous leg ulcer patients943may predispose to venous leg ulcer. Wound repair and regeneration : official publication of the Wound944Healing Society [and] the European Tissue Repair Society 16, 495-502, doi:10.1111/j.1524-945475X.2008.00394.x (2008).
- 94679Rose, G. et al. Metabolism and successful aging: Polymorphic variation of syndecan-4 (SDC4) gene947associate with longevity and lipid profile in healthy elderly Italian subjects. Mechanisms of ageing and948development 150, 27-33, doi:10.1016/j.mad.2015.08.003 (2015).
- 94980Bai, M. R. *et al.* Association of common variation in ADD3 and GPC1 with biliary atresia susceptibility.950Aging 12, 7163-7182, doi:10.18632/aging.103067 (2020).
- 95181Potkin, S. G. *et al.* A genome-wide association study of schizophrenia using brain activation as a<br/>quantitative phenotype. *Schizophrenia bulletin* **35**, 96-108, doi:10.1093/schbul/sbn155 (2009).
- 95382Nadanaka, S., Kagiyama, S. & Kitagawa, H. Roles of EXTL2, a member of the EXT family of tumour<br/>suppressors, in liver injury and regeneration processes. The Biochemical journal 454, 133-145,<br/>doi:10.1042/bj20130323 (2013).
- 95683Purnomo, E. et al. Glycosaminoglycan overproduction in the aorta increases aortic calcification in<br/>murine chronic kidney disease. Journal of the American Heart Association 2, e000405,<br/>doi:10.1161/jaha.113.000405 (2013).
- 95984Martin, P. J. *et al.* Replication of associations between genetic polymorphisms and chronic graft-<br/>versus-host disease. *Blood* **128**, 2450-2456, doi:10.1182/blood-2016-07-728063 (2016).
- 96185Ostrovsky, O. *et al.* The HPSE Gene Insulator-A Novel Regulatory Element That Affects Heparanase962Expression, Stem Cell Mobilization, and the Risk of Acute Graft versus Host Disease. Cells 10,963doi:10.3390/cells10102523 (2021).
- 96486Ostrovsky, O., Shimoni, A., Rand, A., Vlodavsky, I. & Nagler, A. Genetic variations in the heparanase965gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation:966effect of discrepancy between recipients and donors. *Blood* **115**, 2319-2328, doi:10.1182/blood-2009-96708-236455 (2010).
- 96887Oshima, K. et al. Loss of endothelial sulfatase-1 after experimental sepsis attenuates subsequent969pulmonary inflammatory responses. American journal of physiology. Lung cellular and molecular970physiology **317**, L667-I677, doi:10.1152/ajplung.00175.2019 (2019).
- 97188Taghizadeh, E. *et al.* SULF 1 gene polymorphism, rs6990375 is in significant association with fetus972failure in IVF technique. *Iranian journal of reproductive medicine* **13**, 215-220 (2015).

- 97389Zhang, P. et al. Polymorphisms in Sex Hormone Metabolism Genes and Risk of Preeclampsia in<br/>Taiyuan, China. Gynecologic and obstetric investigation 83, 179-186, doi:10.1159/000478931 (2018).
- 975 90 Kamimura, K. & Maeda, N. Glypicans and Heparan Sulfate in Synaptic Development, Neural Plasticity, 976 and Neurological Disorders. *Front Neural Circuits* **15**, 595596, doi:10.3389/fncir.2021.595596 (2021).
- 977 91 Lugert, S. *et al.* Glypican-2 levels in cerebrospinal fluid predict the status of adult hippocampal 978 neurogenesis. *Scientific reports* **7**, 46543, doi:10.1038/srep46543 (2017).
- 97992Luxardi, G. *et al.* Glypicans are differentially expressed during patterning and neurogenesis of early<br/>mouse brain. *Biochem Biophys Res Commun* **352**, 55-60, doi:10.1016/j.bbrc.2006.10.185 (2007).
- 98193Chorąży, M. *et al.* Analysis of chosen SNVs in GPC5, CD58 and IRF8 genes in multiple sclerosis982patients. Advances in medical sciences 64, 230-234, doi:10.1016/j.advms.2018.12.004 (2019).
- 98394Guan, Y. *et al.* The Role of Cell Growth-Related Gene Copy Number Variation in Autoimmune Thyroid984Disease. *Biological trace element research* **195**, 409-416, doi:10.1007/s12011-019-01880-7 (2020).
- 98595Okamoto, K. *et al.* Common variation in GPC5 is associated with acquired nephrotic syndrome. Nature<br/>genetics 43, 459-463, doi:10.1038/ng.792 (2011).
- 98796Bush, K. T. *et al.* N-sulfation of heparan sulfate regulates early branching events in the developing988mammary gland. The Journal of biological chemistry 287, 42064-42070,989doi:10.1074/jbc.M112.423327 (2012).
- 99097Ledin, J. et al. Enzymatically active N-deacetylase/N-sulfotransferase-2 is present in liver but does not<br/>contribute to heparan sulfate N-sulfation. The Journal of biological chemistry 281, 35727-35734,<br/>doi:10.1074/jbc.M604113200 (2006).
- 99398Ledin, J. *et al.* Heparan sulfate structure in mice with genetically modified heparan sulfate production.994The Journal of biological chemistry **279**, 42732-42741, doi:10.1074/jbc.M405382200 (2004).
- 99599Lencz, T. et al. Genome-wide association study implicates NDST3 in schizophrenia and bipolar<br/>disorder. Nature communications 4, 2739, doi:10.1038/ncomms3739 (2013).
- 997100Pallerla, S. R. *et al.* Altered heparan sulfate structure in mice with deleted NDST3 gene function. The<br/>Journal of biological chemistry **283**, 16885-16894, doi:10.1074/jbc.M709774200 (2008).
- 999101Wang, L. et al. Association study of NDST3 gene for schizophrenia, bipolar disorder, major depressive<br/>disorder in the Han Chinese population. American journal of medical genetics. Part B,<br/>Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics<br/>1002100110021002177, 3-9, doi:10.1002/ajmg.b.32573 (2018).
- 1003102Eicher, J. D. *et al.* Genome-wide association study of shared components of reading disability and<br/>language impairment. *Genes, brain, and behavior* **12**, 792-801, doi:10.1111/gbb.12085 (2013).
- 1005103Jao, T. M. et al. Alteration of colonic epithelial cell differentiation in mice deficient for glucosaminyl N-<br/>deacetylase/N-sulfotransferase 4. Oncotarget 7, 84938-84950, doi:10.18632/oncotarget.12915<br/>(2016).
- 1008104Guo, Y. *et al.* Downregulation of HS6ST2 by miR-23b-3p enhances matrix degradation through p381009MAPK pathway in osteoarthritis. *Cell death & disease* 9, 699, doi:10.1038/s41419-018-0729-0 (2018).
- 1010105Paganini, L. *et al.* A HS6ST2 gene variant associated with X-linked intellectual disability and severe<br/>myopia in two male twins. *Clinical genetics* **95**, 368-374, doi:10.1111/cge.13485 (2019).
- 1012106Iwase, M. et al. Differential Effect of Polymorphisms on Body Mass Index Across the Life Course of<br/>Japanese: The Japan Multi-Institutional Collaborative Cohort Study. Journal of epidemiology **31**, 172-<br/>179, doi:10.2188/jea.JE20190296 (2021).
- 1015107Wang, K. S., Wang, L., Liu, X. & Zeng, M. Association of HS6ST3 gene polymorphisms with obesity<br/>and triglycerides: gene x gender interaction. Journal of genetics **92**, 395-402 (2013).
- 1017108Desikan, R. S. *et al.* Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer1018Disease. *Circulation* 131, 2061-2069, doi:10.1161/circulationaha.115.015489 (2015).
- 1019109Shworak, N. W., HajMohammadi, S., de Agostini, A. I. & Rosenberg, R. D. Mice deficient in heparan1020sulfate 3-O-sulfotransferase-1: normal hemostasis with unexpected perinatal phenotypes.1021Glycoconjugate journal 19, 355-361, doi:10.1023/a:1025377206600 (2002).
- 1022110Witoelar, A. *et al.* Meta-analysis of Alzheimer's disease on 9,751 samples from Norway and IGAP1023study identifies four risk loci. Scientific reports 8, 18088, doi:10.1038/s41598-018-36429-6 (2018).
- 1024111Azuara, D. et al. Novel methylation panel for the early detection of neoplasia in high-risk ulcerative<br/>colitis and Crohn's colitis patients. Inflammatory bowel diseases 19, 165-173, doi:10.1002/ibd.22994<br/>(2013).

- 1027112Yu, H., Guo, W., Liu, Y. & Wang, Y. Immune Characteristics Analysis and Transcriptional Regulation1028Prediction Based on Gene Signatures of Chronic Obstructive Pulmonary Disease. International journal1029of chronic obstructive pulmonary disease 16, 3027-3039, doi:10.2147/copd.s325328 (2021).
- 1030 113 Amraoui, F. *et al.* Placental expression of heparan sulfate 3-O-sulfotransferase-3A1 in normotensive 1031 and pre-eclamptic pregnancies. *Placenta* **36**, 1218-1224, doi:10.1016/j.placenta.2015.09.008 (2015).
- 1032114Huang, J. et al. Identification of gene and microRNA changes in response to smoking in human airway<br/>epithelium by bioinformatics analyses. Medicine **98**, e17267, doi:10.1097/md.000000000017267<br/>(2019).
- 1035115Joubert, B. R., Franceschini, N., Mwapasa, V., North, K. E. & Meshnick, S. R. Regulation of CCR51036expression in human placenta: insights from a study of mother-to-child transmission of HIV in Malawi.1037*PloS one* **5**, e9212, doi:10.1371/journal.pone.0009212 (2010).
- 1038116Spencer, K. L. *et al.* Dissection of chromosome 16p12 linkage peak suggests a possible role for<br/>CACNG3 variants in age-related macular degeneration susceptibility. *Investigative ophthalmology & visual science* **52**, 1748-1754, doi:10.1167/iovs.09-5112 (2011).
- 1041117Wang, Q. et al. Genome-wide association analysis with gray matter volume as a quantitative<br/>phenotype in first-episode treatment-naive patients with schizophrenia. PloS one 8, e75083,<br/>doi:10.1371/journal.pone.0075083 (2013).
- 1044118Bork, K. *et al.* Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene1045mutation. J Allergy Clin Immunol, doi:10.1016/j.jaci.2021.01.011 (2021).
- 1046119Santacroce, R., D'Andrea, G., Maffione, A. B., Margaglione, M. & d'Apolito, M. The Genetics of<br/>Hereditary Angioedema: A Review. Journal of clinical medicine **10**, doi:10.3390/jcm10092023 (2021).
- 1048120Jiang, Z., Michal, J. J., Wu, X. L., Pan, Z. & MacNeil, M. D. The heparan and heparin metabolism1049pathway is involved in regulation of fatty acid composition. International journal of biological sciences10507, 659-663, doi:10.7150/ijbs.7.659 (2011).
- 1051121Pastor-Pareja, J. C. Atypical basement membranes and basement membrane diversity what is<br/>normal anyway? *Journal of cell science* **133**, doi:10.1242/jcs.241794 (2020).
- 1053 122 McCarthy, K. J. The Basement Membrane Proteoglycans Perlecan and Agrin: Something Old, 1054 Something New. *Current topics in membranes* **76**, 255-303, doi:10.1016/bs.ctm.2015.09.001 (2015).
- 1055123Greenbaum, L., Alkelai, A., Zozulinsky, P., Kohn, Y. & Lerer, B. Support for association of HSPG2 with<br/>tardive dyskinesia in Caucasian populations. The pharmacogenomics journal 12, 513-520,<br/>doi:10.1038/tpj.2011.32 (2012).
- 1058124Li, L. *et al.* Genetic polymorphisms in collagen-related genes are associated with pelvic organ1059prolapse. Menopause (New York, N.Y.) 27, 223-229, doi:10.1097/gme.00000000001448 (2020).
- 1060
   125
   Fico, A., Maina, F. & Dono, R. Fine-tuning of cell signaling by glypicans. Cell Mol Life Sci 68, 923-929, doi:10.1007/s00018-007-7471-6 (2011).
- 1062126Topaloudi, A. et al. Myasthenia gravis genome-wide association study implicates AGRN as a risk1063locus. Journal of medical genetics, doi:10.1136/jmedgenet-2021-107953 (2021).
- 1064127Rygh, C. B. et al. Image-based assessment of microvascular function and structure in collagen XV-1065and XVIII-deficient mice. The Journal of physiology 592, 325-336, doi:10.1113/jphysiol.2013.2635741066(2014).
- 1067128Sierksma, A. *et al.* Novel Alzheimer risk genes determine the microglia response to amyloid-β but not<br/>to TAU pathology. *EMBO molecular medicine* **12**, e10606, doi:10.15252/emmm.201910606 (2020).
- 1069129Jen, Y. H., Musacchio, M. & Lander, A. D. Glypican-1 controls brain size through regulation of fibroblast<br/>growth factor signaling in early neurogenesis. Neural development 4, 33, doi:10.1186/1749-8104-4-<br/>33 (2009).
- 1072 130 Chung, H., Multhaupt, H. A., Oh, E. S. & Couchman, J. R. Minireview: Syndecans and their crucial roles during tissue regeneration. *FEBS letters* **590**, 2408-2417, doi:10.1002/1873-3468.12280 (2016).
- 1074131Hong, H. et al. Up-regulation of syndecan-2 in proximal colon correlates with acute inflammation.1075FASEB journal : official publication of the Federation of American Societies for Experimental Biology,1076fj201900561R, doi:10.1096/fj.201900561R (2019).
- 1077132Tsoyi, K. et al. Syndecan-2 Attenuates Radiation-induced Pulmonary Fibrosis and Inhibits Fibroblast1078Activation by Regulating PI3K/Akt/ROCK Pathway via CD148. American journal of respiratory cell and1079molecular biology 58, 208-215, doi:10.1165/rcmb.2017-00880C (2018).
- 1080 133 Stacey, D., Ciobanu, L. G. & Baune, B. T. A systematic review on the association between 1081 inflammatory genes and cognitive decline in non-demented elderly individuals. *European*

- 1082 *neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* **27**, 1083 568-588, doi:10.1016/j.euroneuro.2015.12.017 (2017).
- 1084134Echtermeyer, F. et al. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4.1085The Journal of clinical investigation **107**, R9-r14, doi:10.1172/jci10559 (2001).
- 1086135Sivasami, P. et al. Adipose tissue loss and lipodystrophy in xylosyltransferase II deficient mice.1087International journal of obesity (2005) 43, 1783-1794, doi:10.1038/s41366-019-0324-1 (2019).
- 1088136Afratis, N. A. *et al.* Syndecans key regulators of cell signaling and biological functions. *The FEBS*<br/>*journal* **284**, 27-41, doi:10.1111/febs.13940 (2017).
- 1090137Agere, S. A., Kim, E. Y., Akhtar, N. & Ahmed, S. Syndecans in chronic inflammatory and autoimmune<br/>diseases: Pathological insights and therapeutic opportunities. Journal of cellular physiology 233, 6346-<br/>6358, doi:10.1002/jcp.26388 (2018).
- 1093 138 Gopal, S. Syndecans in Inflammation at a Glance. *Frontiers in immunology* **11**, 227, doi:10.3389/fimmu.2020.00227 (2020).
- 1095 139 Stepp, M. A., Pal-Ghosh, S., Tadvalkar, G. & Pajoohesh-Ganji, A. Syndecan-1 and Its Expanding List of Contacts. *Advances in wound care* **4**, 235-249, doi:10.1089/wound.2014.0555 (2015).
- 1097140Mizumoto, S., Yamada, S. & Sugahara, K. Human genetic disorders and knockout mice deficient in<br/>glycosaminoglycan. *BioMed research international* **2014**, 495764, doi:10.1155/2014/495764 (2014).
- 1099141Hayes, A. J. & Melrose, J. Aggrecan, the Primary Weight-Bearing Cartilage Proteoglycan, Has<br/>Context-Dependent, Cell-Directive Properties in Embryonic Development and Neurogenesis:<br/>Aggrecan Glycan Side Chain Modifications Convey Interactive Biodiversity. *Biomolecules* 10, 1244,<br/>doi:10.3390/biom10091244 (2020).
- 1103142Lauing, K. L. et al. Aggrecan is required for growth plate cytoarchitecture and differentiation.1104Developmental biology **396**, 224-236, doi:10.1016/j.ydbio.2014.10.005 (2014).
- 1105143Ponighaus, C. et al. Human xylosyltransferase II is involved in the biosynthesis of the uniform<br/>tetrasaccharide linkage region in chondroitin sulfate and heparan sulfate proteoglycans. The Journal<br/>of biological chemistry 282, 5201-5206, doi:10.1074/jbc.M611665200 (2007).
- 1108144Halper, J. Proteoglycans and diseases of soft tissues. Advances in experimental medicine and biology1109802, 49-58, doi:10.1007/978-94-007-7893-1\_4 (2014).
- 1110145Gulberti, S. et al. Phosphorylation and sulfation of oligosaccharide substrates critically influence the<br/>activity of human beta1,4-galactosyltransferase 7 (GalT-I) and beta1,3-glucuronosyltransferase I<br/>(GlcAT-I) involved in the biosynthesis of the glycosaminoglycan-protein linkage region of<br/>proteoglycans. The Journal of biological chemistry 280, 1417-1425, doi:10.1074/jbc.M411552200<br/>(2005).
- 1115146Klein, J. A., Meng, L. & Zaia, J. Deep Sequencing of Complex Proteoglycans: A Novel Strategy for1116High Coverage and Site-specific Identification of Glycosaminoglycan-linked Peptides. *Mol Cell*1117*Proteomics* 17, 1578-1590, doi:10.1074/mcp.RA118.000766 (2018).
- 1118147Condac, E. et al. Polycystic disease caused by deficiency in xylosyltransferase 2, an initiating enzyme<br/>of glycosaminoglycan biosynthesis. Proceedings of the National Academy of Sciences of the United<br/>States of America 104, 9416-9421, doi:10.1073/pnas.0700908104 (2007).
- 1121148Tsutsui, Y., Ramakrishnan, B. & Qasba, P. K. Crystal structures of beta-1,4-galactosyltransferase 71122enzyme reveal conformational changes and substrate binding. The Journal of biological chemistry1123288, 31963-31970, doi:10.1074/jbc.M113.509984 (2013).
- 1124 149 Liu, X. *et al.* Inactivation of Fam20b in the neural crest-derived mesenchyme of mouse causes multiple craniofacial defects. *European journal of oral sciences* **126**, 433-436, doi:10.1111/eos.12563 (2018).
- 1126150Vogel, P. et al. Amelogenesis imperfecta and other biomineralization defects in Fam20a and Fam20c1127null mice. Veterinary pathology 49, 998-1017, doi:10.1177/0300985812453177 (2012).
- 1128151Huber, C. et al. Identification of CANT1 mutations in Desbuquois dysplasia. American journal of human<br/>genetics 85, 706-710, doi:10.1016/j.ajhg.2009.10.001 (2009).
- 1130152Liu, J., Xu, W., Li, S., Sun, R. & Cheng, W. Multi-omics analysis of tumor mutational burden combined1131with prognostic assessment in epithelial ovarian cancer based on TCGA database. International1132journal of medical sciences 17, 3200-3213, doi:10.7150/ijms.50491 (2020).
- 1133 153 Izumikawa, T. *et al.* GlcUAbeta1-3Galbeta1-3Galbeta1-4Xyl(2-O-phosphate) is the preferred 1134 substrate for chondroitin N-acetylgalactosaminyltransferase-1. *The Journal of biological chemistry* 1135 **290**, 5438-5448, doi:10.1074/jbc.M114.603266 (2015).

- 1136154Orellana, A., Moraga, C., Araya, M. & Moreno, A. Overview of Nucleotide Sugar Transporter Gene1137Family Functions Across Multiple Species. Journal of molecular biology 428, 3150-3165,1138doi:10.1016/j.jmb.2016.05.021 (2016).
- 1139155Parker, J. L. & Newstead, S. Gateway to the Golgi: molecular mechanisms of nucleotide sugar<br/>transporters. *Current opinion in structural biology* **57**, 127-134, doi:10.1016/j.sbi.2019.03.019 (2019).
- 1141 156 Anthony, S., Munk, R., Skakun, W. & Masini, M. Multiple epiphyseal dysplasia. *The Journal of the American Academy of Orthopaedic Surgeons* **23**, 164-172, doi:10.5435/jaaos-d-13-00173 (2015).
- 1143157Winawer, M. R. et al. Somatic SLC35A2 variants in the brain are associated with intractable neocortical<br/>epilepsy. Annals of neurology 83, 1133-1146, doi:10.1002/ana.25243 (2018).
- 1145158Pacifici, M. The pathogenic roles of heparan sulfate deficiency in hereditary multiple exostoses. Matrix<br/>Biol 71-72, 28-39, doi:10.1016/j.matbio.2017.12.011 (2018).
- 1147159Debarnot, C. et al. Substrate binding mode and catalytic mechanism of human heparan sulfate d-<br/>glucuronyl C5 epimerase. Proceedings of the National Academy of Sciences of the United States of<br/>America 116, 6760-6765, doi:10.1073/pnas.1818333116 (2019).
- 1150160Dou, W., Xu, Y., Pagadala, V., Pedersen, L. C. & Liu, J. Role of Deacetylase Activity of N-1151Deacetylase/N-Sulfotransferase 1 in Forming N-Sulfated Domain in Heparan Sulfate. The Journal of1152biological chemistry **290**, 20427-20437, doi:10.1074/jbc.M115.664409 (2015).
- 1153161Habuchi, H. *et al.* The occurrence of three isoforms of heparan sulfate 6-O-sulfotransferase having<br/>different specificities for hexuronic acid adjacent to the targeted N-sulfoglucosamine. The Journal of<br/>biological chemistry **275**, 2859-2868, doi:10.1074/jbc.275.4.2859 (2000).
- 1156162Jemth, P. et al. Oligosaccharide library-based assessment of heparan sulfate 6-O-sulfotransferase<br/>substrate specificity. The Journal of biological chemistry 278, 24371-24376,<br/>doi:10.1074/jbc.M212155200 (2003).
- 1159163Sheng, J., Liu, R., Xu, Y. & Liu, J. The dominating role of N-deacetylase/N-sulfotransferase 1 in forming<br/>domain structures in heparan sulfate. The Journal of biological chemistry 286, 19768-19776,<br/>doi:10.1074/jbc.M111.224311 (2011).
- 1162164Kjellen, L. Glucosaminyl N-deacetylase/N-sulphotransferases in heparan sulphate biosynthesis and<br/>biology. *Biochemical Society transactions* **31**, 340-342, doi:10.1042/bst0310340 (2003).
- 1164165Billings, P. C. & Pacifici, M. Interactions of signaling proteins, growth factors and other proteins with<br/>heparan sulfate: mechanisms and mysteries. Connective tissue research 56, 272-280,<br/>doi:10.3109/03008207.2015.1045066 (2015).
- 1167166Reuter, M. S. et al. NDST1 missense mutations in autosomal recessive intellectual disability. American<br/>journal of medical genetics. Part A 164a, 2753-2763, doi:10.1002/ajmg.a.36723 (2014).
- 1169167Takahashi, I. *et al.* Important role of heparan sulfate in postnatal islet growth and insulin secretion.1170Biochem Biophys Res Commun 383, 113-118, doi:10.1016/j.bbrc.2009.03.140 (2009).
- 1171168Kunnas, T., Solakivi, T., Määttä, K. & Nikkari, S. T. Glucuronic Acid Epimerase (GLCE) Variant1172rs3865014 (A>G) Is Associated with BMI, Blood Hemoglobin, Hypertension, and Cerebrovascular1173Events, the TAMRISK Study. Annals of human genetics 80, 332-335, doi:10.1111/ahg.12166 (2016).
- 1174 169 Lee, H. *et al.* Whole Genome Analysis of the Red-Crowned Crane Provides Insight into Avian Longevity. *Molecules and cells* **43**, 86-95, doi:10.14348/molcells.2019.0190 (2020).
- 1176170Borjigin, J. et al. Diurnal pineal 3-O-sulphotransferase 2 expression controlled by beta-adrenergic1177repression. The Journal of biological chemistry 278, 16315-16319, doi:10.1074/jbc.M3008282001178(2003).
- 1179171Vanpouille, C. *et al.* The heparin/heparan sulfate sequence that interacts with cyclophilin B contains a<br/>3-O-sulfated N-unsubstituted glucosamine residue. *The Journal of biological chemistry* 282, 24416-<br/>24429, doi:M701835200 [pii]
- 1182 10.1074/jbc.M701835200 (2007).
- 1183 172 Rönnberg, E., Melo, F. R. & Pejler, G. Mast cell proteoglycans. The journal of histochemistry and 1184 cytochemistry : official journal of the Histochemistry Society 60. 950-962, doi:10.1369/0022155412458927 (2012). 1185
- 1186173Nguyen, N. T. *et al.* Genetic and enzymatic characterization of 3-O-sulfotransferase SNPs associated<br/>with Plasmodium falciparum parasitaemia. *Glycobiology* 28, 534-541, doi:10.1093/glycob/cwy038<br/>(2018).
- 1189 174 Osorio, S., Rivillas, N. D. & Martinez, J. A. Urofacial (ochoa) syndrome: A literature review. *Journal of pediatric urology* **17**, 246-254, doi:10.1016/j.jpurol.2021.01.017 (2021).

- 1191175Woolf, A. S., Stuart, H. M. & Newman, W. G. Genetics of human congenital urinary bladder disease.1192Pediatric nephrology (Berlin, Germany) 29, 353-360, doi:10.1007/s00467-013-2472-1 (2014).
- 1193
   176 Chen, H., Wang, T., Yang, J., Huang, S. & Zeng, P. Improved Detection of Potentially Pleiotropic
   Genes in Coronary Artery Disease and Chronic Kidney Disease Using GWAS Summary Statistics.
   *Frontiers in genetics* 11, 592461, doi:10.3389/fgene.2020.592461 (2020).
- 1196177Deligny, A. et al. NDST2 (N-Deacetylase/N-Sulfotransferase-2) Enzyme Regulates Heparan Sulfate<br/>Chain Length. The Journal of biological chemistry **291**, 18600-18607, doi:10.1074/jbc.M116.744433<br/>(2016).
- 1199178Huang, Y. C. et al. Genome-wide association study of diabetic retinopathy in a Taiwanese population.1200Ophthalmology 118, 642-648, doi:10.1016/j.ophtha.2010.07.020 (2011).
- 1201179Espinosa, A. *et al.* Exploring Genetic Associations of Alzheimer's Disease Loci With Mild Cognitive<br/>Impairment Neurocognitive Endophenotypes. *Frontiers in aging neuroscience* **10**, 340,<br/>doi:10.3389/fnagi.2018.00340 (2018).
- 1204180Shworak, N. W., Kobayashi, T., de Agostini, A. & Smits, N. C. Anticoagulant heparan sulfate to not1205clot-or not? Progress in molecular biology and translational science **93**, 153-178, doi:10.1016/s1877-12061173(10)93008-1 (2010).
- 1207181Sepulveda-Diaz, J. E. *et al.* HS3ST2 expression is critical for the abnormal phosphorylation of tau in<br/>Alzheimer's disease-related tau pathology. *Brain : a journal of neurology* **138**, 1339-1354,<br/>doi:10.1093/brain/awv056 (2015).
- 1210182Atkinson, A., Garnier, S., Afridi, S., Fumoux, F. & Rihet, P. Genetic variations in genes involved in<br/>heparan sulphate biosynthesis are associated with Plasmodium falciparum parasitaemia: a familial<br/>study in Burkina Faso. *Malaria journal* **11**, 108, doi:10.1186/1475-2875-11-108 (2012).
- 1213183Mackinnon, M. J. *et al.* Environmental Correlation Analysis for Genes Associated with Protection<br/>against Malaria. *Molecular biology and evolution* **33**, 1188-1204, doi:10.1093/molbev/msw004 (2016).
- 1215184Howard, S. R. et al. HS6ST1 Insufficiency Causes Self-Limited Delayed Puberty in Contrast With<br/>Other GnRH Deficiency Genes. The Journal of clinical endocrinology and metabolism 103, 3420-3429,<br/>doi:10.1210/jc.2018-00646 (2018).
- 1218185Hayashi, S. *et al.* Comprehensive investigation of CASK mutations and other genetic etiologies in 411219patients with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH).1220*PloS one* **12**, e0181791, doi:10.1371/journal.pone.0181791 (2017).
- 1221186Poon, I. K. et al. Mice deficient in heparanase exhibit impaired dendritic cell migration and reduced<br/>airway inflammation. European journal of immunology 44, 1016-1030, doi:10.1002/eji.201343645<br/>(2014).
- 1224 187 Holst, C. R. *et al.* Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse 1225 neonatal survival. *PloS one* **2**, e575, doi:10.1371/journal.pone.0000575 (2007).
- 1226188Hassing, H. C. *et al.* SULF2 strongly prediposes to fasting and postprandial triglycerides in patients1227with obesity and type 2 diabetes mellitus. Obesity (Silver Spring, Md.) 22, 1309-1316,1228doi:10.1002/oby.20682 (2014).
- 1229189Matikainen, N. et al. Genetic variation in SULF2 is associated with postprandial clearance of<br/>triglyceride-rich remnant particles and triglyceride levels in healthy subjects. PloS one 8, e79473,<br/>doi:10.1371/journal.pone.0079473 (2013).
- 1232190Duchez, S. et al. Glycotranscriptome study reveals an enzymatic switch modulating1233glycosaminoglycan synthesis during B-cell development and activation. European journal of1234immunology 41, 3632-3644, doi:10.1002/eji.201140865 (2011).
- 1235191Mizumoto, S., Yamada, S. & Sugahara, K. Mutations in Biosynthetic Enzymes for the Protein Linker1236Region of Chondroitin/Dermatan/Heparan Sulfate Cause Skeletal and Skin Dysplasias. BioMed1237research international 2015, 861752, doi:10.1155/2015/861752 (2015).
- 1238192Esko, J. D. & Selleck, S. B. Order out of chaos: assembly of ligand binding sites in heparan sulfate.1239Annual review of biochemistry **71**, 435-471, doi:10.1146/annurev.biochem.71.110601.135458 (2002).
- 1240193Gesslbauer, B., Rek, A., Falsone, F., Rajkovic, E. & Kungl, A. J. Proteoglycanomics: tools to unravel<br/>the biological function of glycosaminoglycans. *Proteomics* 7, 2870-2880, doi:10.1002/pmic.200700176<br/>(2007).
- 1243194Aikawa, J., Grobe, K., Tsujimoto, M. & Esko, J. D. Multiple isozymes of heparan sulfate/heparin1244GlcNAc N-deacetylase/GlcN N-sulfotransferase. Structure and activity of the fourth member, NDST4.1245The Journal of biological chemistry **276**, 5876-5882, doi:10.1074/jbc.M009606200 (2001).
- 1246 195 Habuchi, H. *et al.* Biosynthesis of heparan sulphate with diverse structures and functions: two alternatively spliced forms of human heparan sulphate 6-O-sulphotransferase-2 having different

- expression patterns and properties. *The Biochemical journal* **371**, 131-142, doi:10.1042/bj20021259
  (2003).
- 1250196Lawrence, R. *et al.* The principal neuronal gD-type 3-O-sulfotransferases and their products in central<br/>and peripheral nervous system tissues. *Matrix Biol* **26**, 442-455, doi:10.1016/j.matbio.2007.03.002<br/>(2007).
- 1253
   197 Li, Y. J. *et al.* Characterization of heparan sulfate N-deacetylase/N-sulfotransferase isoform 4 using synthetic oligosaccharide substrates. *Biochimica et biophysica acta. General subjects* 1862, 547-556, doi:10.1016/j.bbagen.2017.11.016 (2018).
- 1256 198 Mochizuki, H. *et al.* Characterization of a heparan sulfate 3-O-sulfotransferase-5, an enzyme 1257 synthesizing a tetrasulfated disaccharide. *The Journal of biological chemistry* **278**, 26780-26787, 1258 doi:10.1074/jbc.M301861200 (2003).
- 1259
  199
  1260
  1261
  199
  199 Sheng, J., Xu, Y., Dulaney, S. B., Huang, X. & Liu, J. Uncovering biphasic catalytic mode of C5epimerase in heparan sulfate biosynthesis. *The Journal of biological chemistry* 287, 20996-21002, doi:10.1074/jbc.M112.359885 (2012).
- Rudd, T. R. & Yates, E. A. A highly efficient tree structure for the biosynthesis of heparan sulfate accounts for the commonly observed disaccharides and suggests a mechanism for domain synthesis.
   *Molecular bioSystems* 8, 1499-1506, doi:10.1039/c2mb25019e (2012).

1265